 
I8F-MC-GPHI Clinical Pharmacology Protocol  
 
 Effect of Injection Site on the Relative Bioavailability of a  Single Dose of Tirzepatide in  
Subjects with Low and High Body Mass Indices 
 
[STUDY_ID_REMOVED] 
 
 Date: 27-Jun-2019 
 
I8F-MC-GPHI Clinical Pharmacology Protocol Page 1
Tirzepatide (LY 3298176 )Protocol I8F-MC-GPHI
Effect of Injection Site on the Relative Bioavailability  ofa
Single Dose of Tirzepatide in Subjects with Low and High 
Body  Mass Indices
Confidential Information
The information contained in this protocol is confidential and is intended for the use of 
clinical investigators.  It is the property of Eli Lilly and Company or its subsidiaries and 
should not be copied by or distributed to persons not involved in the cli nical investigation of 
tirzepatide (LY3298176), unless such persons are bound by a confidentiality agreement 
with Eli Lilly and Company or its subsidiaries.
Note to Regulatory Authorities:   This document may contain protected personal data 
and/or commercia lly confidential information exempt from public disclosure.  Eli Lilly and 
Company requests consultation regarding release/redaction prior to any public release.  In 
the United States, this document is subject to Freedom of Information Act Exemption 4 and 
may not be reproduced or otherwise disseminated without the written approval of Eli Lilly 
and Company or its subsidiaries.
Tirzepa tide (LY3298176)
Eli Lilly and Company
Indianapolis, Indiana USA 46285
Clinical Pharmacology Protocol Electronically Signed and Approved by Lilly on date 
provided below .
Approval Date: 27-Jun-2019 GMT
I8F-MC-GPHI Clinical Pharmacology Protocol Page 2
Tirzepatide (LY 3298176 )Table of Contents
Effect of Injection Site on the Relative Bioavailability  of a 
Single Dose of Tirzepatide in Subjects with Low and High 
Body  Mass Indices
Section Page
Protocol  I8F-MC-GPHI Effect of Inject ion Site on the Rel ative 
Bioavailabilit y of a Single Dose of Tirzepat ide in Subjects with Low 
and High Body  Mass Indices ............................................................................................... 1
Table of Contents ........................................................................................................................ 2
1. Protocol  Synopsi s................................................................................................................ 8
2. Schedule of Act ivities....................................................................................................... 10
3. Intro duction ...................................................................................................................... 13
3.1. Study  Rati onale ............................................................................................................ 13
3.2. Background .................................................................................................................. 13
3.3. Benefit/Risk Assessment .............................................................................................. 14
4. Object ives and Endpo ints.................................................................................................. 15
5. Study  Design ..................................................................................................................... 16
5.1. Overall Design ............................................................................................................. 16
5.2. Number of Participants .................................................................................................18
5.3. End of Study  Definit ion............................................................................................... 18
5.4. Scientific Rationale for Study  Design ........................................................................... 18
5.5. Justification for Dose ................................................................................................... 18
6. Study  Popul ation............................................................................................................... 19
6.1. Inclusio n Cri teria.......................................................................................................... 19
6.2. Exclu sion Criteria........................................................................................................ 21
6.3. Lifest yle and/or Dietary Requirements ......................................................................... 23
6.3.1. Meals and Dietary  Restri ctions............................................................................. 23
6.3.2. Caffeine, Alcoho l, and Tobacco ........................................................................... 24
6.3.3. Activity................................................................................................................ 24
6.4. Screen Failures ............................................................................................................. 24
7. Treatment .......................................................................................................................... 25
7.1. Treatment Admin istered ............................................................................................... 25
7.1.1. Packaging and Labeling ....................................................................................... 25
7.1.2. Medical Devices ................................................................................................... 26
7.2. Metho d of Treatment Assignment ................................................................................ 26
7.2.1. Selection and Timing o f Doses ............................................................................. 26
I8F-MC-GPHI Clinical Pharmacology Protocol Page 3
Tirzepatide (LY 3298176 )7.3. Blinding ....................................................................................................................... 26
7.4. Dose Modificat ion........................................................................................................ 26
7.5. Prepa ration/Handling/Storage/Accountabilit y............................................................... 26
7.6. Treatment Compliance .................................................................................................26
7.7. Concomitant Therapy ................................................................................................... 26
7.8. Treatment After the End of the Study ........................................................................... 27
8. Discontinuati on Cri teria .................................................................................................... 28
8.1. Discontinuati on from Study  Treatm ent......................................................................... 28
8.1.1. Discontinuati on of  Inadvertent ly Enrolled Subjects .............................................. 28
8.2. Discontinuati on from the Study .................................................................................... 28
8.3. Subjects Lost to Follow -up........................................................................................... 29
9. Study  Assessments and Procedures ................................................................................... 30
9.1. Efficacy Assessments ................................................................................................... 30
9.2. Adverse Events ............................................................................................................ 30
9.2.1. Serious Adverse Events ........................................................................................ 31
9.2.1.1. Suspected Unexpected Serious Adverse React ions.......................................... 32
9.2.2. Com plaint Handling ............................................................................................. 32
9.3. Treatment of Overdose .................................................................................................32
9.4. Safety........................................................................................................................... 32
9.4.1. Clinical Laboratory  Tests ..................................................................................... 32
9.4.1.1. Amylase and Lipase Measurements ................................................................ 32
9.4.2. Glucose Moni toring ............................................................................................. 33
9.4.2.1. Hyperglycemia and Hy poglycemia Reporting ................................................. 33
9.4.3. Vital Signs ........................................................................................................... 34
9.4.4. Electrocardiograms .............................................................................................. 35
9.4.5. I nject ion-Site Reacti ons ....................................................................................... 35
9.4.6. Hypersensi tivity Reacti ons................................................................................... 36
9.4.7. Safety Moni toring ................................................................................................ 36
9.4.7.1. Hepati c Safet y................................................................................................ 37
9.5. Pharmacokinet ics......................................................................................................... 37
9.5.1. Bioanalysis ........................................................................................................... 37
9.5.2. Exploratory  Assessments ..................................................................................... 38
9.5.2.1. Fat Deposit ion at Inject ion Site....................................................................... 38
9.5.2.2. Waist, Upper Arm, and Thigh Circumferen ce................................................. 38
9.6. Pharmacodynamics ...................................................................................................... 38
9.7. Immunogenicit y Assessments ....................................................................................... 38
9.8. Genet ics....................................................................................................................... 39
9.9. Biomarkers ................................................................................................................... 40
I8F-MC-GPHI Clinical Pharmacology Protocol Page 4
Tirzepatide (LY 3298176 )9.10. Health Economics ........................................................................................................ 40
10. Statistical Considerati ons and Data Analysis ..................................................................... 41
10.1. Sample Si ze Determinat ion.......................................................................................... 41
10.2. Popul ations for Analyses .............................................................................................. 41
10.2.1. Study  Parti cipant Disposit ion............................................................................... 41
10.2.2. Study  Parti cipant Characterist ics.......................................................................... 41
10.3. Statistical Analyses ...................................................................................................... 41
10.3.1. Safety Analyses .................................................................................................... 41
10.3.1.1. Clinical Evaluation of Safet y.......................................................................... 41
10.3.1.2. Statistical Evaluat ion of Safet y....................................................................... 42
10.3.2. Pharmacokinet ic Analyses .................................................................................... 42
10.3.2.1. Pharmacokinet ic Parameter Estimat ion........................................................... 42
10.3.2.2. Pharmacokinet ic Statistical Inference ............................................................. 42
10.3.3. Evaluat ion of Immunogenicit y............................................................................. 43
10.3.4. Data Review During the Study ............................................................................. 44
10.3.5. Interim Analyses .................................................................................................. 44
11. References ........................................................................................................................ 45
12. Appendices ....................................................................................................................... 46
I8F-MC-GPHI Clinical Pharmacology Protocol Page 5
Tirzepatide (LY 3298176 )List of Tables
Table Page
Table GPHI.1. Object ives and Endpo ints....................................................................... 15
Table GPHI.2. Treatments Administered via Autoinjector .............................................. 25
I8F-MC-GPHI Clinical Pharmacology Protocol Page 6
Tirzepatide (LY 3298176 )Listof Figures
Figure Page
Figure GPHI.1. Illustrati on of  Study  Design for Protocol I8F -MC-GPHI. ........................ 17
I8F-MC-GPHI Clinical Pharmacology Protocol Page 7
Tirzepatide (LY 3298176 )List of Appendices
Appendix Page
Appendix 1. Abbreviat ions and Definit ions................................................................ 47
Appendix 2. Clinical Laboratory  Tests ........................................................................ 51
Appendix 3. Study  Governance, Regulatory  and Ethi cal Considerati ons..................... 52
Appendix 4. Hepati c Moni toring Tests for Treatment -Emergent Abnormalit y............ 55
Appendix 5. Blood Sam pling Summary ...................................................................... 56
Appendix 6. Classificat ion of Contraceptive Methods ................................................. 57
Appendix 7. Pancreat ic Monitoring ............................................................................ 58
I8F-MC-GPHI Clinical Pharmacology Protocol Page 8
Tirzepatide (LY 3298176 )1.Protocol Synopsis
Title of Study:
Effect of Injection Site on the Relative Bioavailability of a Single Dose of Tirzepatide in Subjects with Low and 
High Body Mass Ind ices.
Rationale: 
Study I8F -MC -GPHI (GPHI) will investigate the effect of injection site on the relative bioavailability of a single 
5mg dose of tirzepatide injected subcutaneously (SC) into the upper arm (Test 1) or thigh (Test 2) compared to SC 
injection into the abdomen (Reference ).  During previous Phase 1 and Phase 2 clinical trials, tirzepatide has been 
administered by SC injection into the abdome n.  However, patients in clinical practice may prefer to self -administer 
tirzepatide at different body sites.   In addition, a difference in adiposity and/or absorption profile may lead to 
increased variability and suboptimal glycemic contro l.  This will be explored in the current study by enrolling 
subjects with both low and high body mass indices (BMI).
Objectives/Endpoints:
Objectives Endpoints
Primary
To determine the relative bioavailability of SC 
tirzepatide 5 mg injection into the thigh and upper arm 
compared to the abdomen.AUC(0 -∞) and C max
Secondary
To determine the relative bioavailability of SC 
tirzepatide 5 mg injection in subjects with different 
BMIs.
To evaluate the safety and tolerability of SC tirzepatide 
5 mg injection.AUC(0 -∞) and C max
Incidence of TEAEs
Abbreviations:  AUC(0 -∞) = area under the concentration versus time curve from zero to infinity; B MI = body mass 
index; C max= maximum drugconcentration; SC = subcutaneous; TEAE = treatment -emergent adverse event .
Summary of Study Design :
This is a single -center, open -label, 3 -period, 3 -sequence, randomized, crossover study conducted in overtly healthy 
male and female subjects in 2 BMI groups (low [18.5 to 27.0 kg/m 2] and high [27.1 to 45.0 kg/m 2]).  
Treatment Arms and Planned Duration foran Individual Subject :  
The study  involves a comparison of:
A single dose of 5 mg tirzepatide administered SC to the upper arm (Test 1) versus a single dose of 5 mg 
tirzepatide administered SC to the abdomen (Reference)
A single dose of 5 mg tirzepatide administered SC to the thigh (Test 2) versus a single dose of 5 mg 
tirzepatide administered SC to the abdomen (Reference)
I8F-MC-GPHI Clinical Pharmacology Protocol Page 9
Tirzepatide (LY 3298176 )The study  duration for individual subjects, inclusive of screening is expected to be approximately 20 weeks, divided
as follows: 
Screening:   up to 27 days prior to Day -1
Treatment Periods 1, 2, and 3:   Day 1 to Day  36, including single dosing with tirzepatide on Day 1 of each 
Treatment Period
Washout:   at least 35 days between tirzepatide injections
Follow -up:  Treatment Period 3, Day 36 will be considered the final follow -up visit
Number of Subjects :
Approximately 54 subjects will be enrolled to ensure that at least 36 evaluable subjects complete the study , with at 
least 12 subjects completeing per treatment sequence . 
Statistical Analysis:
The primary pharmacokinetic parameters for analysis will be C maxandAUC(0 -∞).
Pharmacokinetic parameter estimates will be evaluated to delineate effects of injection site.   Log -transformed 
AUC(0 -∞)and C maxwill be evaluated in a lin earmixed -effects model with fixed effects for injection site, period, 
and sequence.  Subject nested within sequence will be fitted as a random effec t.  Differences will be 
back-transformed to present the ratios of geometric least squares means and the cor responding 90% confidence 
interval (CI).
For the primary endpoint, a model comparing the differences between the upper arm (Test 1) and the abdomen 
(Reference) and between the thigh (Test 2) and the abdomen (Reference) will be use d.  For the secondary endpoint, 
BMI group and the BMI group -by-injection site interaction term will be added to the above mode l.  
Allinvestigational product and protocol procedure adverse events ( AEs)and study device complaints will be listed, 
and if the frequency of events allows, safety data will be summarized using descriptive methodology.
Safety parameters that will be assessed include AE, safety lab oratoryparameters (including amylase, lipase, and 
blood glucose), and vital signs.  The parameters will be listed and summa rized using s tandard descriptive statistics , 
where appropriate .  Physical examinations and electrocardiograms will be performed for safety monitoring purposes 
and will not be presente d.  
Incidence of er ythema, induration, pain, itching, and edema will be listed and summarize d.  
Additional analyses may be performed, if appropriate.
I8F-MC-GPHI Clinical Pharmacology Protocol Page 10
Tirzepatide (LY 3298176 )2.Schedule of A ctivities
I8F-MC-GPHI Clinical Pharmacology Protocol Page 11
Tirzepatide (LY 3298176 )Study Schedule Protocol I8F -MC -GPHI
Screening Treatment Periods 1 to 3Study Days (≥35 days washout between Day 1 doses ) EDc Comments
ProcedureD-28 to
D-2D-1b D1 D2 D3 D4 D5 D6 D7 D8 D15 D21D36
(±1)b
Informed Consent X
Subject Admission to 
CRUX
Subject Discharge 
from CRUXSubjects’ CRU stay may be extended at the 
investigator’s discretion for safety monitoring.
Outpatient Visit X X X X X
Tirzepatide Dosing 0 hour Study  drug will be administered after an overnight 
fast of at least 8hours.
Medical History X
Physical Examination 
/Medical AssessmentX X X X X Full p hysical examination at screening. Thereafter, 
targeted review s and medical assessments as 
appropriate.
Weight and Height X X X X Height is required to be taken at screening only .
Temperature X Predose
Safety 12 -Lead ECG 
(hours postdose )aX Predose 24 72 X X X Single safety ECG swill be collecte d.  ECGs must be 
recorded before collecting any blood samples.  
Subjects must be supine for approximately 5 to 
10minutes before ECG collection, and remain 
supine but awake during ECG collection.
Supine Vital Signs 
(hours postdose )aX Predose,
1224 48 72 X X X X X Additional time points may be added, if warranted 
and agreed upon between Lilly and the investigator.
Clinical Laboratory 
TestsX X X X X X X See Appendix 2 for details. Subjects will be fasted at 
least 8 hours before sampling.
Urine Drug Screen X X
Alcohol Breath Test X
Pregnancy Test X X X X Female subjects onl y.  See Appendix 2 for details.
AEs/Concomitant 
MedicationsX X X X X X X X X X X X X X
Waist , Upper Arm,
and Thigh 
Circumference and 
Skinfold ThicknessX Circumference of the injection site for the specific 
period should be measured in triplicate and the mean
recorde d.  W aist circumference is measured for the 
abdomen injection site. 
Fat Deposition 
Assessment at 
Injection Site - DEXA 
Scan X DEXA scan of the relevant injection site may be 
performed any time between Day -4and Day -1.
Pharmacogenetic 
SampleaPredose Single sample in Treatment Period 1 only.
I8F-MC-GPHI Clinical Pharmacology Protocol Page 12
Tirzepatide (LY 3298176 )Screening Treatment Periods 1 to 3Study Days (≥35 days washout between Day 1 doses ) EDc Comments
ProcedureD-28 to
D-2D-1b D1 D2 D3 D4 D5 D6 D7 D8 D15 D21D36
(±1)b
PK Sampling
(hours postdose )aPredose,
8, 1224, 
3648 72 96 120 144 168 336 480 X X Up to a 10% deviation from the nominal collection
time is permissible as long as actual sampling time is 
recorded.
Blood Glucose 
Monitoring
(hours postdose )aPredose,
1224, 
3648 72 Performed using a bedside glucose monitor.  
Additional unscheduled measurements may be taken 
at the discretion of the investigator where clinically 
indicated.
Immunogenicity a Predose X X X Where applicable, collection times should match 
with PK sampling time points .In the event of 
immediate or non -immediate drug hypersensitivity 
reactions , unscheduled samples will be collected as 
detailed in Section 9.4.6 .  Subjects with clinically 
significant TEADA at follow -up/ED will undergo 
additional follow -upas detailed in Section 9.7.
Abbreviations:  AE = adverse event; CRU = clinical research unit; D = Day; DEXA = dual energy x-ray  absorptiometry ;ECG =electrocardiogram; ED = early 
discontinuation; PK =pharmacokinetic(s); TE ADA = treatment -
emergent anti -drugantibodies.  
Note:  All sampling times are given relative to dosing (Time 0 hour) with tirzepatide (predose or hours postdose ).  Unless otherwise indicated, predose procedure 
may be performed any time prior to dosing.
If multiple procedures take place at the same time point, the following order of the procedures should be used:  ECGs, vital signs, PK sample (record of actual 
PK sampling time isthepriority ), clinical laboratory sample, immunogenicity, DEXA scan, blood glucose ,and pharmacogenetic sample.
aSpecified times are approximate and actual times will be recorde d.  Actual sampling /assessment time should not exceed 1 hour prior to dosing for the predose 
sample /assessment .
bThe Day  36 visit of a treatment period may occur at the same time as the Day -1 visit of the subsequent treatment period, therefore assessments that occur on 
both visits will only be performed once.  All results must be reviewed prior to dosing on Day 1 of each treatment perio d.  The Day  36 visit of Treatment 
Period 3 will be considered the final follow -up visi t.  
cWithin 14 days upon confirmation of early discontinuation.
I8F-MC-GPHI Clinical Pharmacology Protocol Page 13
Tirzepatide (LY 3298176 )3.Introduction
3.1. Study Rationale
Tirzepati de is being developed for the treatm ent oftype 2 diabetes m ellitus (T2DM) as an 
adjunct to di et and exercise .  In addition, it is being developed as a therapy  for the indicat ions of 
chronic weight management and nonalcoho lic steatohepatit is (NASH ).  It is administered once
weekly by subcuteanous (SC)inject ion.
Study  I8F-MC-GPHI (GPHI) will invest igate the effect of inject ion site on the relative 
bioavailabilit y of a single 5 mg dose of tirzepat ide injected SC into the upper arm (Test 1) or 
thigh (Test 2) com pared to SC inject ion into the abdom en(Reference).
During previous Phase 1 and Phase 2 clinical trials, tirzepat ide has been administered by SC
inject ion into the abdom en.  H owever, patients in clinical pract ice may prefer to self -administer 
tirzepat ide at different body  sites.  
In addit ion, a difference in adiposit y and/or absorption profile may lead to increased variabilit y 
and suboptimal glycemic contro l.  This will be explored in the current study  by enrolling subjects 
with both l ow and high body  mass indices (BMI s), measuring skinfo ld thickness with skinfo ld 
calipers, and dual energy  x-ray absorpti ometry (DEXA) scanning to estimate fat deposit ion at 
their inject ion site locations.
3.2. Background
The available preclinical and clinical data indicate that co- stimulat ion of glucose -dependent 
insulinotropic polypept ide (GIP) and glucagon -like peptide -1 (GLP -1)receptors may enhance 
insulin secret ion, improve insulin sensit ivity, and reduce body  weight bey ond the effect of 
select ive GLP -1 receptor stimulat ion (Frias et a l.  2018; Coskun et al.  2018).  
Tirzepati de is a 39 -amino acid synt hetic peptide, dual GIP and GLP -
1 receptor agonis t.  Its 
structure is based on the GIP sequence and includes a C20 fatty di -acid m oiety that prol ongs the 
durati on of  action.  It has a chemical structure a nd pharmaco logic profile that i s dist inct from the 
GLP -1 receptor agonists due to the addition of  GIP, whi ch is uni que am ong the m arketed incretin 
mimet ics.
In a Phase 1 study  (Coskun et a l.  2018) that included single and mult iple ascending dose (SAD, 
MAD) parts, tirzepat idehas been administered as single SC doses up to 8mg in healt hy subjects . 
In the MAD part, higher doses up to 10 mg were attained in healt hy subjects via dose escalat ion.  
Doses up to 15 mg were achieved in pat ients with T2DM via dose escalat ion.
In theabove -ment ioned study , gastrointestinal (GI) adverse events (AEs) (nausea, vo miting, 
diarrhea, abdo minal distensio n) and decreased appetite were the most frequent ly reported events 
by both healt hy subjects and pat ients with T2DM and were dose relate d.  Most AEs were mild in 
severit y, a few were m oderate, and none were reported as severe.  During the SAD study , the 
high incidence of GI AEs, notably vo miting, were considered to be dose limit ing at the 8 -mg 
dose; therefore, the 5-mg dose was considered the maximum tolerated dose (MTD) .  
I8F-MC-GPHI Clinical Pharmacology Protocol Page 14
Tirzepatide (LY 3298176 )A dose -dependent increase in heart rate was detected for both healt hy subjects and pat ients with 
T2DM who received t irzepat ide, similar to what was observed with select ive GLP -1 receptor 
agonists .  A few subjects experienced transient elevat ions in lipase and/or amylase levels, but 
these episodes were not associated with any relevant clinical outcomes . 
Once -weekly doses of 1, 5, 10, and 15 mg have been further investigated in a Phase 2 study  
(Frias et al , 2018 ).  An addit ional dose l evel of 12 mg and alternate dose escalat ion schemes 
were invest igated in a 12 -week Phase 2 study.   Doses abov e 5 m g of tirzepat ide were attained via 
step-wise dose escalation .   Results from the two Phase 2 studies demonstrated that tirzepat ide at 
doses between 5 and 15 mg provided clinically meaningful efficacy in both glucose -and body  
weight
-lowering .  Gastrointestinal -related AEs (nausea, diarrhea, vomit ing) were the most 
frequently reported AEs in Phase 2 studies.  The majority  of the treatm ent-emergent adverse 
events (TEAEs) were mild or moderate in severi ty. 
There were no other clinically relevant safet y observat ions in the Phase 1 and 2 studies.
Tirzepati de terminal half -life was estimated to be approximately 5 days, thus supporting a 
once -weekly dosing regimen, with maximu m drug concentration (C max) occurring 24 to 
72hours post dose.  
Overall, the safet y and tol erabilit y, and pharmacokinet ic (PK)/pharmacodynamic ( PD)profiles of 
tirzepat idesupport further development of tirzepat idein patients with T2DM .  Further details can 
be found in the Invest igator’s Brochure (IB) .
3.3. Benefit/Risk Assessment
Risks of t irzepat ide have been consistent with risks associated with other GLP -1 receptor 
agonists currently  markete d.  Potenti al risks include, but are not limited to, GI effects, acute 
pancreat itis, increases in heart rate, and hypoglycemic events (GLP -1 receptor agonist class 
effect).
No clinically  significant safet y or tol erabilit y concerns have been identified during cl inical 
investigat ion of t irzepat ide up to the highest single -dose l evel of 8 mg or m ultipleweekly doses, 
when t itrated up to 15 mg. Based on this inf ormation, the 3 × single 5- mg doses to be 
administered in Study GPHI , in subjects with low and high BMIs, are reasonably anticipated to 
be tol erable in this group of otherwise healthy subjects.
There i s no antici pated therapeuti c benefi t for the subjects.
More informat ion about the known and expected benefits, risks, serious adverse events (SAEs) 
and reasonably ant icipated AEs of tirzepat ide are to be found in the IB.
I8F-MC-GPHI Clinical Pharmacology Protocol Page 15
Tirzepatide (LY 3298176 )4.Objectives and Endpoints
Table GPHI .1shows the object ives and endpo ints of the study .
Table GPHI .1. Objectives and Endpoints
Objectives Endpoints
Primary
To determine the relative bioavailability of SC 
tirzepatide 5-mg injection into the thigh and upper arm 
compared to the abdom en.AUC(0-∞) and Cmax
Secondary
To determine the relative bioa vailability of SC 
tirzepatide 5 -mg injection in subjects with different 
BMIs.
To evaluate the safety and tolerability o f SC tirzepatide 
5-mg injection.AUC(0-∞) and C max
Incidence of TE
AEs 
Exploratory
To explore the relationship between adiposity at 
injection site with tirzepatide exposure .AUC(0-∞) and Cmax
Abbreviations: AUC(0 -∞) =area under the concentration versus time curve from zero to infinity ; BMI = body mass 
index; C max= maximum drugconcentration ; SC = subcutaneous ; TEAE = treatment -emergent adverse event .
I8F-MC-GPHI Clinical Pharmacology Protocol Page 16
Tirzepatide (LY 3298176 )5.Study  Design
5.1. OverallDesign
This is a single -center , open -label, 3-period, 3-sequence, randomized ,crossover study  conducted 
in overtly healt hy male and female subjects in 2 BMI groups (l ow and high ).  The BMI groups 
will be as fo llows:
Low BMI:  18.5 to 27.0 kg/m 2
High BMI:  27.1 to 45.0 kg/m 2: every  effort will be m ade to enroll subjects so that
approximately  halfof this group have a BMI above 35.0 kg/m 2
Subjects will be admitted to the clinical research unit ( CRU )on Day  -1 and will receive a single 
SC inject ion of tirzepat ide 5 mg into 1 of 3 inject ion sites on Day 1,of each of the 3 treatment 
periods, wi th injecti on si te sequence determined by  the randomizat ion.
The inject ion sites are :
upper arm (Test 1 )
thigh (Test 2)
abdo men (Reference)
Subjects will remain in the CRU until the scheduled assessments have been completed on Day  8.  
Subjects may be required to remain inpat ient for a longer period if deemed necessary by the 
investigator for safet y monitoring reasons.   
Subjects will attend 3 outpatient visits on Days 15, 
21, and 36 of each treatment period for safet y monitoring and PK sampling .  The Day  36 visit of 
Treatment Period 3 will be considered the final fo llow-up visi t.  
There will be a washout period of at least 35 days between tirzepat ide injections.
Pharmacokinet ic blood sampling and s afety assessments, including vital sign measurement s, 
physical examinat ions, clinical laboratory  tests, glucose monitoring, electrocardi ograms ( ECGs ),
inject ion site reactions, hypersensit ivity react ions,and AE recording will be perform ed according 
to the Schedul e of Activities(Secti on 2).
Study governance considerations are described in detail in Appendix 3 .
Figure GPHI .
1illustrates the study desig n.  This tirzepatide inject ion sequenc e shown is an 
illustrative example onl y.  E ach subject enrolled will be assigned a treatment sequence according 
to the actual rando mizat ion schedule provided to the site.
I8F-MC-GPHI Clinical Pharmacology Protocol Page 17
Tirzepatide (LY 3298176 )Figure GPHI .1. Illustration of Study D esign for Protocol I8F-MC-GPHI .

I8F-MC-GPHI Clinical Pharmacology Protocol Page 18
Tirzepatide (LY 3298176 )5.2. Number of Participants
Approximately 54subjects will be enro lled in the study to ensure that at least 1 2evaluable 
subjects in each treatment sequence complete the 3 treatment periods. Approximately equal 
numbers of subjec ts wi th high and l ow BMI will  be enrolled in each treatment sequence . 
For purposes of this study , a subject completes the study  when all  scheduled procedures shown 
in the Schedule of Act ivities (Secti on 2) have b een finished.
5.3. End of Study Definition
End of the study is the date of the last visit or last scheduled procedure shown in the Schedule o f 
Activities(Secti on 2) for the last subject .
5.4. Scientific Rationale for Study Design
A healt hy subject populat ion will allow assessments of the PK, safet y, and tol erabili ty of 
tirzepat ide with a reduced likelihood o f physi ologic variabili ty.  A lso, healthy subjects are 
usually devo id of other confounding factors, such as concomitant medicat ion.
In order to minimize any potential period -effect and to allow each subject to act as his/her own 
control , a randomized, 3-sequence, crossover design has been selecte d.  Awashout period of at 
least 35 days between doses is considered sufficient to minimize any carry over of  tirzepat ide 
concentrations from one period into the next period.
This study  will be open -label as the study  primary  endpo intPK m easures are obj ective rather 
than subject ive.
5.5. Justification for Dose
Results from the Phase 1 study ,GPGA ,indicate the 5 -mg dose of tirzepat ide was well tol erated 
by healthy subjects and patients with T2DM, and is also pl anned as one of the doses to be 
investigated in Phase 3 studies.   Doses higher than 5 mg were achieved via step-wise dose 
escalat ion and a 5-mg dose was considered the MTD when administered as a single dose.
I8F-MC-GPHI Clinical Pharmacology Protocol Page 19
Tirzepatide (LY 3298176 )6.Study  Population
Eligibilit y of subjects for the study  will be based on the results of screening medical history , 
physical examinat ion, vital signs, clinical laboratory tests and EC G.  
The nature of any condit ions present at the time of the physical examinat ion and any pr eexist ing 
condi tions will  be docum ented.
Screening may occur up to 28 days prior to enrollmen t.  Subjects who are not enrolled within 
28days of screening may  be subjected to an addit ional medical assessment and/or clinical 
measurements to confirm their el igibilit y.
If the invest igator decides not to administer the dose to a subject or not to enroll a subject on a 
particular day , the subject’s visit may  be rescheduled (e.g. ,to another cohort) and any 
assessments or procedures performed up to that point may be repeated to confirm their 
eligibilit y.
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, are not permitted.
6.1. Inclusion Criteria
Subjects are eligible for inclusio n in the study  only if they  meet all  of the f ollowing criteria at 
screening and/or Day -
1, unl ess stated otherwise :
[1] are overtly healt hy males or females, as determined by  medical history  and 
physical examinat ion
.
[1a] male subjects: men, regardless of their fertilit y status, with non -pregnant 
wom en of childbearing potential partners must agree to either remain 
abstinent (if this is their preferred and usual lifest yle) or use condoms plus 
one addi tional highly  effect ive(less than 1% failure rate) method of 
contraception (such as co mbination oral contraceptives, implanted 
contraceptives, or intrauterine device) or effect ive method of contraception 
(such as diaphragms wit h spermicide or cervical sponge) for the duration o f 
the study  and f or at least 90 days after dosing.   A full list of permitted highly  
effect ive and effect ive methods of contraception is presented in Appendix 6 .
oMen and their partners may  choose to use a double -barrier method of 
contraceptio n.  Barrier protecti on methods wi thout concomitant use of 
a spermicide are not an effect ive or acceptable method of 
contraceptio n.  Thus, each barrier method must include use of a 
spermicide.  It should be noted, however, that the use of male and 
female condo ms as a double -barrier m ethod is not considered 
acceptable due to the high failure rate when these barrier methods are 
combined.
oPeriodic abst inence (e .g., calendar, ovul ation, symptothermal, 
post-ovulation methods), decl aration of  abstinence just for the duration 
I8F-MC-GPHI Clinical Pharmacology Protocol Page 20
Tirzepatide (LY 3298176 )of a study , and wi thdrawal  are not acceptabl e methods of 
contraception.
oMen wi th pregnant partners should use condoms during intercourse for 
the durati on of  the study  and unt il the end of est imated relevant 
potenti al exposure in wo men of childbearing potential.
oMen who are in exclusively same -sex rel ationships (as their preferred 
and usual lifest yle) are not required to use contraception.
oMen should refr ain from sperm  donat ion for the durati on of  the study  
and for at least 90 day safter dosing.
[1b] female subject s: wom en of  childbearing potent ial are excluded fro m the 
study.  Women not of childbearing potential may  parti cipate and include 
those who are:
A.infertile due to surgical sterilizat ion (hysterectomy, bilateral oophorectomy, or 
tubal  ligation), congenital ano maly such as m ullerian agenesis; or
B.postm enopausal –defined as eit her:
i. A wo man at l east 50 years of age with an intact uterus, not on hormone
therapy , who has had either:
a)cessat ion of menses for at least 1 y ear, or
b)at least 6 m onths of spontaneous amenorrhea with a 
follicle -stimulat ing horm one >40 IU/mL; or
ii. A wo man 55 or older not on hormone therapy , who has had at l east 
6months of spontaneous amenorrhea; or
iii. A wo man at l east 55 years of age with a diagnosis of menopause prior to 
starting hormone replacement therapy .
[2] are between 18and 70 y ears of age, inclusive, at the time of screening.
[3] have a BMI of:
o18.5 to 27.0 kg/m 2, inclusive (low BMI group), or 
o27.1 to 45.0 kg/m 2, inclusive (high BMI group).
[
4] h ave clinical laboratory  test resul ts wi thin norm al reference range for the 
popul ation or invest igativesite, or resul ts wi th acceptabl e deviat ions that are 
judged to be n ot clinically significant by  the investigator .
[
5] have venous access sufficient to allow for blood sampling as per the protocol .
[6] a re willing to receive study treatment by SC inject ions.
[
7]have given written informed consent approved by Lilly and the institutional 
review board ( IRB) governing the site.
I8F-MC-GPHI Clinical Pharmacology Protocol Page 21
Tirzepatide (LY 3298176 )[8] have blood pressure, pulse rate, and an ECG reading that are considered to be 
within norm al reference range for the popul ation or investi gativesite, or 
resul ts wi th acceptable deviat ions that are j udged to be not clinically  
significant by  the invest igator .
6.2. Exclusion Criteria
Subjects will be excluded fro m study  enro llment if they meet any o f the following cri teria at 
screening and/or Day -1, unl ess stated otherwise :
[
9] are invest igativesite personnel  direct ly affiliated with this study  and thei r 
immediate families.  Immediate family is defined as a spouse, biological or 
legal guardian , child ,or sibling.
[
10] are Lilly  empl oyeesor are em ployees of a thi rd-party  organi zation involved 
with the study .
[11] are currently enrolled in a clinical  study  involving an invest igational product
(IP)or any  other ty pe of medical research judged not to be scient ifically or 
medically co mpat ible with this stud y.  
[12] have received treatment with a dru g that has not received regulatory  approval  
for any  indicati on wi thin 30 days of screening.
[
13] have previ ously  com pleted or wi thdrawn from  this study  or any  other study  
investigat ing tirzepat ide, and have previously received the 
IP.  
[14] h ave had any exposure to ti rzepati de, other GLP -1 analogs, or other related 
compounds wi thin 3 m onthsprior to dosing
, or any  history  of allergies to 
these m edicati ons.
[15] have any abnormalit y in the 12 -lead ECG at screening that, in the opinio n of 
the invest igator, increases the risks associated with participat ing in the stud y.  
[16]have a significant history  of or current cardi ovascular (e .g., myocardial 
infarction, congest ive heart failure, cerebrovascular a ccident, venous 
thromboembo lism), respi ratory , hepat ic, renal, GI, endocrine, hematological 
(including history  of thrombocy topeni a) or neurol ogical disorders capable of 
significant ly altering the absorpti on, m etabo lism, or eliminat ion of drugs, or 
of const ituting a risk when taking the study  medicati on, or of i nterfering with 
the interpretation of data .
[16a] Subjects in the high BMI group with stable medical condit ions (e.g., 
controlled hyperlipidemia and/or hypertensio n, stable fatty liver condit ion) 
may be enro lled if the investigator (or designee) agrees tha t the condit ion 
will not introduce an additional risk factor, and will not interfere with the 
study  object ives, procedures, or PK of tirzepat ide. 
[
17] have evidence of significant active neuropsy chiatric di sease, as determined by  
the invest igator .
I8F-MC-GPHI Clinical Pharmacology Protocol Page 22
Tirzepatide (LY 3298176 )[18] re gularly use known drugs of abuse and/or show posit ive findings on drug 
screening .
[19] have evidence of human immunodeficiency  virus (HIV) infect ion and/or are 
positive for human HIV antibodies.
[20]have evidence of hepatit is C and/or are posit ive for hepat itis C ant ibodies. 
[21]have evidence of hepatit is B and/or are posit ive for hepat itis B surface 
antigen.  
[22]smoke >10 ci garettes per day , or the equivalent, or are unable or unwilling to 
refra in fro m nicotine while resident in the CRU
.
[23]have used or plan to use over -the -coun ter or prescript ion medication, and/or 
herbal supplements (with the except ion of vitamin/mineral supplements, any  
horm one repl acement therapy , and/or thy roid replacem enttherapy) within 
14days prior to dosing and for the duration of the study , including any  
medicat ions that reduce GI motilit y, including, but not limit ed to, 
anticholinergics, ant ispasmodics, 5 -hydroxytryptamine -3 receptor antagonists, 
dopamine antagonists , and opi ates.  Exceptions to this criterion may be made
on a case-by- case basis at the invest igator’s (or designee ’s) discret ion, in 
consultation wit h the Lilly Clinical Pharmaco logist (CP)/Clinical Research 
Physician ( CRP )(or desi gnee ).  
[23a] Subjects in the high BMI group with stable (for at least 3 months pri or to 
screening) doses of lipid -lowering or blood pressure -lowering medicat ions 
may be enro lled if the investigator (or designee) ,in consultat ion with the 
Lilly CP/CRP (or desi gnee) ,where neces sary,agrees that the medication 
will not interfere with the trial objectives, procedures, or PK of tirzepat ide.  
[24] h ave donated blood of more than 450 mL in the last 3 months, have 
participated in a clinical study  that requi red a similar blood volume be drawn 
in the last 3 months, or have had any blood donation within the last month 
prior to screening.
[
25] have an average weekly  alcohol  intakethat exceeds 21 un its per week (males) 
or 14 uni ts per week (females), OR are unwilling to stop alcohol consumpt ion 
24 hours prior to each dosing until discharge from the CRU, and 24 hours 
prior to each outpatient visit (1 uni t of alcoho l = 12 oz or 360 mL of beer; 5 oz 
or 150mL of wine; 1.5 oz or 45 mL of dist illed spirits) .
I8F-MC-GPHI Clinical Pharmacology Protocol Page 23
Tirzepatide (LY 3298176 )[26] have a history  or presence of pancreat itis (history of chronic pancreat itis or 
idiopathic acute pancreat itis), elevat ion in serum amylase or lipase (>1.5 -fold 
the upper limit of normal [ULN]), GI disorder (e.g. , relevant esophageal 
reflux or gall bladder disease), or any  GI di sease which impacts gastric 
emptying (e .g., gastric bypass surgery, pyloric stenosis [with the except ion of 
appendectomy ]) or coul d be aggravated by  GLP -analogs or dipept idyl 
pepti dase IV (DPP -IV) inhibitors.  Subjects with dyslipidemia and subjects 
who had cho lecystolit hiasis (wit h rem oval of gallstones) ,cholecystectomy 
(removal of the gall bladder) ,and/oruncomplicated appendectomy or hernia 
repai rin the past, with no furt her sequelae, may be included in the study , at 
the discret ion of the invest igator.
[27] have a history  of Gilbert’s syndrom e or clinical laboratory  resul
ts that are 
suggest ive o fGilbert’s syndro me.
[28] have a history  of atopy  or clinically  significant m ultiple or severe drug 
allergies, intolerance to topical corticosteroids, or severe posttreatment 
hypersensit ivity react ions (including, but not limited to, erythema mult iforme 
major, linear immunoglobulin A dermatosis, toxic epidermal necrolysis, or 
exfoliative dermat itis).
[
29] have a personal or family history  of medullary  thyroi d carcino ma or have 
multiple endocrine neoplasia syndro me type 2.
[
30] have serum aspartate aminotransferase (AST) or alanine aminotransferase 
(ALT) >3 × ULN or total bilirubin ( TBL) >2 × ULN.
[
31] have a history  of malignancy wit hin 5 years prior to screening.
[32] havea serum  triglyceri de (TG) ≥5mmo l/L (442.5 mg/dL) at screening.
[33] h ave been treated with prescription drugs that promote weight loss (e . g., 
Meri dia®[sibutramine], Sanorex®[mazindo l], Adipex®[phentermine], 
Belviq®[lorcaserin], My simba®[naltrexone/bupropion], Saxenda®
[liraglut ide]),or similar other body  weight l oss medi cations, including 
over-the
-counter m edicat ions (e .g., Alli®) within 3 mo nths prior to screening.
[34]are deem ed unsui table by the invest igator for any other reason.
6.3. Lifestyle and/or Dietary Requirements
Throughout the study , subjects m ay undergo m edical  assessments and review of compliance with 
requi rements before continuing in the stud y.  
6.3.1. Meals and Dietary Restrictions
Subjects will be required to fast overnight for at least 8 hours before being given any  SC dose of 
tirzepat ide, and when clinical laboratory test samples are taken (see Schedule of Activit ies, 
Secti on2).  A meal will be offered to study subjects at around 2 hours postdose.  During 
inpat ient stays, subjects m ay not consume any food other than that provided by  the CR U.  W ater 
may be consumed freely.
I8F-MC-GPHI Clinical Pharmacology Protocol Page 24
Tirzepatide (LY 3298176 )6.3.2. Caffeine, Alcohol, and Tobacco 
No al coho l will be allowed fro m 24 hours prior to each dosing unt il discharge from the CRU , 
and 24 hours prior to each outpatient visi t.  No nicotine /tobacco use will be permitted while in 
the CR U.  W hile not residen t in the CRU, subjects must not consume more than 10 cigarettes or 
the equivalent per day .
Subjects will be allowed to maintain the regular caffeine consumption throughout the study  
period (except during specific fast ing time periods).
6.3.3. Activity
No strenuou s phy sical act ivity will be allowed for 48 hours prior to each dosing unt il discharge 
from the CRU, and 24 hours prior to each outpatient visit.
6.4. Screen Failures
Individuals who do not meet the criteria for participation in this study  (screen failure) m ay not be 
re-screene d.  H owever, s creening tests such as clinical laboratory  tests and vi tal signs/ECGs may  
be repeated once at the discret ion of the invest igator.  
I8F-MC-GPHI Clinical Pharmacology Protocol Page 25
Tirzepatide (LY 3298176 )7.Treatment
7.1. Treatment Administ ered
This study  involves a comparison of tirzepati deadministered as single 5-mg SCinject ions
delivered via an autoinjector to theupper armand thigh in co mpar ison to the abdo men.  
Table GPHI .
2shows the treatment re gimens.
When administered in the abdo men, the inject ion will be administered to the lower abdominal 
quadrant, approximately  5cm from the umbilicus . Detailed instructions for use of the 
autoinjector will be provided by the sponsor.  Only a limited number of clinical site staff will 
perform  the SC administrati on for consistency reasons. 
Table GPHI .2. Treatment sAdministered via A utoinjector
Treatment Name Test 1 Test 2 Reference
Injection Site upper arm thigh abdom en
Dosage Formulation solution for injection solution for injection solution for injection
Dose 5mg tirzepatide / 0.5 mL 5mg tirzepatide / 0.5 mL 5mg tirzepatide / 0.5 mL
Route of 
AdministrationSC injection SC injection SC injection
Delivery Method autoinjector autoinjector autoinjector
Abbreviations:  SC = subcutaneous
The investigator or clinical site designee is responsible for:
explaining the correct use of the IPto the clinical staff .
verifying that instructions are fo llowed properly .
maintaining accurate records of IPdispensing and collect ion.
returning all unused medication to Lilly  or its designee at the end of the study .
Note : In some cases, sites may destroy  the m aterial  if, during the invest igativesite select ion, the 
evaluator has verified and documented that the site has appropriate facilit ies and wri tten 
procedures to dispose of clinical materials .
7.1.1. Packaging and Labeling
Tirzepati de will  be supplied by  the sponsor or i ts designee in accordance w ith current good 
manufacturing practice, labeled according to the country ’s regul atory  requi rements.
I8F-MC-GPHI Clinical Pharmacology Protocol Page 26
Tirzepatide (LY 3298176 )Each ti rzepat ide autoinjector is designed to deliver 5 mg of tirzepatide.
7.1.2. Medical Devices
The invest igator or designee will ensure that the instructions ha ve been fo llowed properly; 
maintaining accurate records of study  devices, di spensing, and collection. The used or unused 
autoinjectors may be destroy ed by  a qualified vendor. 
7.2. Method of Treatment Assignment
Subjects will be rando mly assigned to 1 of 3 treatment sequences based on injection site and 
stratified into 2 groups based on BMI ( 18.5 to 27.0kg/m 2and 27.1 to 45.0 kg/m 2, inclusive )
using a co mputer -generated allocat ion code.
7.2.1. Selection and Timing of Doses
The actual  time of all dose administrations will be recorded in the subject’s electronic case report 
form (eCRF).
7.3. Blinding
This study  is open -label.
7.4. Dose Modification
Dose m odificat ion is not permitted in this study .
7.5. Preparation/Handling/Storage/Accountabi lity
The invest igator or designee must confirm appropriate temperature condit ions have been 
maintained , as communicated by sponsor, during transit for all IPreceived and that 
any 
discrepancies are reported and resolved before use of the study  treatm ent.
Only subjects enrolled in the study  may receive IPor study  materials, and only  authori zed si te 
staff may administer IP.   All IPshoul dbe stored in a nenvironmentally  controlled and m onitored 
(manual  or autom ated) area i n accordance with the labeled storage condit ions wit h access limited 
to the invest igator and authorized site staff .
The invest igator is responsible for study treatment accountabilit y, reconciliat ion, and record 
maintenance ( such as recei pt, reconciliat ion and final disposit ion records ).
7.6. Treatment Compliance
The IP will be administered at the clinical site, and documentation of treatment administration 
will occur at the site.
7.7. Concomitant Therapy
In general, concomitant m edicat ion shoul d be avo ided; however, paracetamo l (up to 1 gper 
dose, maximum 3 g/24 hours) may be administered at the discret ion of the investigator for 
treatm ent of headaches et c.  If the need for concomitant medication (other than paracetam ol) 
arises, inclusio n or continuat ion of the subject may be at the discr etion of  the invest igator , 
I8F-MC-GPHI Clinical Pharmacology Protocol Page 27
Tirzepatide (LY 3298176 )preferably after consul tation wi th a Lilly CP/CRP or desi gnee .  Any  medicat ion used during the 
course of the study  must be docum ented.
For subjects enrolled in the high BMI group, treatment with chronic stable medications that ar e 
necessary  for maintain ing the subjec t’s clinical status will be permitted if approved by  the 
investigator (or designee) and Lilly CP/CR P.  T he subject must have been on a stable dose for a 
minimum o f 3months pri or to screening and throughout the trial, unless required for the 
treatm ent of an A E.  
As per exclusio n criterion 23, vi tamin/mineral  suppl ements, horm one replacement therapy , 
and/or thy roid repl acement therapy  are acceptable concomitant medicat ions during the course of 
the stud y.  
On Day  1 of each treatm ent peri od, administrati on of  medicat ions m ay be wi thhel d for at l east 
2hours predose until 4 hours postdose, as deemed clinically appropriate by the invest igator.   
7.8. Treatment After the End of the Study
Not applicable .
I8F-MC-GPHI Clinical Pharmacology Protocol Page 28
Tirzepatide (LY 3298176 )8.Discontinuation Criteria
Subjects discont inuing fro m the study  and treatm entprematurely for any reason shoul d complete 
AEand other fo llow-up procedures per Schedule of Act ivities (Secti on 2)of this protocol .
8.1. Discontinuation from Study Treatment
Discontinuati on of  the IP for abnormal liver tests should be considered by the invest igator when 
a subject meets 1 of the fo llowing condi tions after consultation wit h the Lilly -designated m edical 
monitor:
ALT or AST >5 ×ULN for healthy subjects 
ALT or AST >3 ×ULN for healthy subjects sustained for more than 2 weeks 
ALT or AST >3 ×ULN and TBL >2 ×ULN or internat ional norm alized rati o>1.5 
ALT or AST >3 ×ULN wit
h the appearance of fat igue, nausea, vomiting, right 
upper -quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)
alkaline phosphatase (ALP) >3 ×ULN
ALP>2.5× ULN and TBL >2 ×ULN
ALP>2.5× ULN wi th the appearance of fat igue, nausea, vo miting, right quadrant pain or 
tenderness, fev er, rash, and/or eosinophilia (>5%)
8.1.1. Discontinuation of Inadvertently Enrolled Subjects
If the sponsor or invest igator ident ifies a subject who did not m eet enrollment cri teria and was 
inadvertent ly enro lled, a discussio n must occur between the Lilly  CP/CRP and the invest igator to 
determine if the subject may cont inue in the stud y.  If both agree it is medically appropriate to 
continue, the invest igator must obtain documented approval fro m the Lilly CP/CRP to allow the 
inadvertent ly enro lled subject to continue in the study  with or wi thout continued treatment with 
IP.  
8.2. Discontinuation from the Study
Subjects will be discont inued in the fo llowing ci rcum stances:
Enrollment in any other clinical study  involving an IP or enrollment in any other type of 
medical research judged not to be scient ifically or medically co mpat ible with this study
Parti cipation in the study  needs to be stopped for medical, safet y, regul atory , or other 
reasons consistent with applicable laws, regulations, and good clinical pract ice (GCP)
Invest igator decision
othe invest igator decides that the subject should be discontinued from the study
Subject d ecision
othe subject, or legal representative, requests to be wi thdrawn from  the study
I8F-MC-GPHI Clinical Pharmacology Protocol Page 29
Tirzepatide (LY 3298176 )8.3. Subjects Lost to Follow -up
A subject will be consi dered l ost to f ollow -up if he or she repeatedly  fails to return for scheduled 
visits and is unable to be con tacted by  the study  site.  Site personnel are expected to make 
diligent attempts to contact subjects who fail to return for a scheduled visit or wer e otherwise 
unable to be fo llowed up by  the si te.
I8F-MC-GPHI Clinical Pharmacology Protocol Page 30
Tirzepatide (LY 3298176 )9.Study Assessments and Procedures
Secti on 2lists the Schedule of Act ivities, detailing the study  procedures and their timing 
(including tolerance limit s for timing).
Appendix 2 lists the clinical laboratory tests that wi ll be perform ed for this study .
Appendix 5 provi des a summary of the approximate number and volume of invasive samples, for
all sampling, during the study .
The specificat ions in this protocol for the timings of safet y and sample co llections are given as 
targets to be achieved wit hin reasonable limits.  Modificat ions may be made to the time po ints 
based upon emerging clinical informat ion.  T he scheduled t ime points may be subject to minor 
alterati ons; however, the actual time must be recorded correctly in the e lectroni c CRF (eCRF ).  
Failure or delays (i.e .,outsi de sti pulated time allo wances) in performing procedures or obtaining 
samples due to legit imate clinical issues (e.g. ,equipment technical problems, venous access 
difficult y, or subject default ing or turning up late on an agreed scheduled procedure) will not be 
considered as protocol deviat ions but the CRU will still be required to notify  the sponsor in 
writing via a file note.
Unless otherwise stated in subsect ions below, all s amples collected for specified laboratory  tests 
will be destroy ed wi thin 60 days of receipt of confirmed test results.  Certain samples may be 
retained for a longer period, if necessary , to com ply with applicable laws, regulat ions, or 
laboratory  certificati on standards.
9.1. Efficacy Assessments
Not applicable.
9.2. Adverse Events
Invest igators are responsible for monitoring the safety of subjects who have entered this study 
and for al erting Lilly  or its designee to any  event that seems unusual, even if this event may be 
considered an unant icipated benefit to the subject.
The invest igator is responsible for the appropriate medical care of subjects during the study.
Invest igators must document their review of each laboratory  safety  report.
The invest igator remains responsible for fo llowing, through an appropriate health care option, 
AEs that are serious or otherwi se medically  important, considered rel ated to the IP or the study , 
or that caused the subject to discontinue the IP before complet ing the stud y.  The subject should 
be followed unt il the event resolves, stabilizes wit h appropriat e diagnosti c evaluat ion, or i s 
reasonably  explaine d.  T he frequency o f follow-up evaluat ions of the AE is left to the discret ion 
of the invest igator.
The invest igator will record all relevant AE and SAE informat ion in the eCR F.  A fter the 
inform ed consent form (ICF) is si gned, study  site personnel will record, via eCRF, the 
occurrence and nature of each subject’s preexist ing conditions, including clinically significant
I8F-MC-GPHI Clinical Pharmacology Protocol Page 31
Tirzepatide (LY 3298176 )signs and symptoms of the disease under treatment in the stud y.  Addi tionally , site personnel will  
record any  change in the condit ion(s) and the occurrence and nature of any  AEs.  
The invest igator will interpret and document whether or not an AE has a reasonable possibilit y 
of being related to study  treatm ent, the autoi njector, and/ or a study  procedure, taking into 
account the disease, concomitant treatment or pathologies.  
A “reasonable possibilit y” means that there is a potential cause and effect relat ionship between 
the IP, study  device and/or study  procedure and the AE.
Planned surgeries should not be reported as AEs unless the underlying medical condit ion has 
worsened during the course of the study .
If a subject’s IP is discont inued as a result of an AE, study  site personnel  must report thi s to Lilly 
or its desi gnee via eCR F.  
9.2.1. Serious Adverse Events 
An SAE is any AE from this study  that resul ts in one of the fo llowing:
death
initial or prolonged inpatient hospitalizat ion
a life- threatening experience (that is, immediate risk of dying)
persistent or significant disa bility/incapacit y
congenital ano maly/birth defect
important medical events that may not be immediately life -threatening or result in death 
or hospitalization but may jeopardize the subject or may requi re interventi on to prevent 
one of the other outcomes li sted in the definit ion above
when a condit ion related to the use of the tirzepat ide autoinjector device necessitates 
medical or surgical intervent ion to precl ude ei ther perm anent impairment of a body  
funct ion or permanent damage to a body  structure, the serious outcom e of “requi red 
intervent ion” will be assigned
Study  site personnel  must al ert the Lilly  CRP/CP, or i ts desi gnee, of  any SAE as soon as 
practi cally  possible.
Addit ionally , study  site personnel  must al ert Lilly  Global Patient Safet y, or its desi gnee, of any  
SAE wi thin 24 hours of invest igator awareness of the event via a sponsor -approved metho d.  If 
alerts are issued via telephone, they  are to be immedi ately fo llowed wi th official notification on 
study -specific SAE forms.  This 24 -hour notificat ion requirement refers to the init ial SAE 
inform ation and all fo llow-up SAE information.
Invest igators are not obligated to actively seek AEs or SAEs in subjects once they have 
discontinued fro m and/or com pleted the study  (the subject summary eCRF has been completed).  
However, if the invest igator learns of any SAE, including a death, at any time after a subject has
I8F-MC-GPHI Clinical Pharmacology Protocol Page 32
Tirzepatide (LY 3298176 )been discharged from the study , and he/she considers the event reasonably  possibly  related to the 
study  treatm ent or study  parti cipat ion, the i nvest igator m ust prom ptly notify Lill y.  
Pregnancy (paternal exposure to IP) does not meet the definit ion of an AE.  H owever, to fulfill 
regul atory  requi rements any  pregnancy shoul d be reported following the SAE process to collect 
data on the outcome for both m other and fetus.
9.2.1.1. Suspected Unexpected Serious Adverse Reactions 
Suspected unexpected serious adverse react ions (SUSARs) are serious events that are not listed 
in the IB and that the investigator reports as related to IP or procedure.  Lilly has proc edures that 
will be fo llowed f or the recording and expedited reporting of SUSARs that are consistent with 
global regulat ions and the associated detailed guidances.
9.2.2. Complaint Handling
Lilly co llects product complaints on IPs and drug delivery systems used in clinical trials in order 
to ensure the safet y of study  partici pants, m onitor quali ty, and to facilitate process and product 
improvements.
Subjects should be instructed to contact th e invest igator as soon as possible if he or she has a 
complaint or probl em wi th the IP or drug delivery  system  so that the si tuation can be assessed.
9.3. Treatment of Overdose
For the purposes of this study , an overdose of ti rzepati de is considered any  dose hi gher than the 
dose assigned through rando mizat ion.
There i s no specific antidote for tirzepatide.  In the event of an overdose, the subject should 
receive appropriate supportive care and any AEs should be documented.
Refer to the I B.
9.4. Safety
9.4.1. Clinical Labora tory Tests
For each subject , clinical laboratory  testsdetailed in Appendix 2 shoul d be conducted according 
to the Schedule of Activities (Secti on2).  
9.4.1.1. Amylase and Lipase Meas urements
Serum  amylase and lipase measurements will be collected as part of the clinical laboratory  
testing and as specified in the Schedule of Activit ies (Secti on 2).  Additional measurements may 
be perform ed at the invest igator’s discretio n.  
Further di agnost ic assessments will be 
recommended as per the algorithm (refer to Appendix 7 )for the m onitoring of pancreat ic events 
whenever lipase and/or amylase is confirmed to be ≥3×ULN at any visit post dose, even if the 
subject is asymptomat ic.
I8F-MC-GPHI Clinical Pharmacology Protocol Page 33
Tirzepatide (LY 3298176 )9.4.2. Glucose Monitoring
For safet y purposes, blood glucose measurements will be performed using a bedside glucose 
monitor as specified in the Schedule of Act ivities (Section 2).  A dditional safety blood glucose 
monitor measurem ents m ay also be taken during the study
 as deemed necessary  by the 
investigator.
9.4.2.1. Hyperglycemia and Hypoglycemia Reporting
Episodes of hyperg lycemia (fasting plasma/serum glucose >270 mg/dL [15 mmo l/L]) or 
hypoglycemia (plasma/serum glucose ≤70mg/dL [3.9 mmo l/L]) will be reported by  the 
investigator or designated physician who will be responsible for advising the subject on what 
further action s to take. Addit ional monitoring may be requested at the invest igator’s discretion.
If the fasting plasma/serum glucose during Treatment Periods 1, 2, and/or 3 exceeds the 
acceptable level defined as hyperglycemia on 3 or more separate day s over any 2- week peri od 
between screening and the end of the dosing period, the subject will be evaluated further at the 
study  site.If fasting plasma/serum glucose continues to exceed the acceptable level, treatment 
with an appropri ate anti diabet ic agent may be init iated by  the invest igator. If hyperglycemia 
occurs duri ng the fo llow
-up peri od, the subject will remain in the study unt il completion of the 
planned fo llow-up.
Hypoglycemia episode s will be recorded on specific eCRF pages. Hypoglycemia will be treated 
appro priately by the investigator and addit ional moni toring of plasma/serum glucose levels may 
be perform ed.  The fo llowing categori es of the 2017 American Diabetes Associat ion posit ion 
statement on glycemic targets ( ADA 2017) based on recommendations of the In ternati onal 
Hypoglycaemia Study  Group (IHSG 2017) should b e applied for reporti ng in the eCRF and 
evaluat ing hypoglycemic events.
Hypoglycemia will be described using the following definit ions:  
Documented Glucose Alert Level (Level 1), Plasma Glucose (PG) ≤70mg/dL 
(3.9mmol/L) :  
oSymptomatic hypoglycemia :  an event during which typical symptoms of 
hypoglycemia are acco mpanied by PG ≤70mg/dL (3.9 mmo l/L)
oAsymptomatic hypoglycemia: an event not accompanied by t ypical symptoms 
of hypoglycemia but with PG ≤70 m g/dL (3.9 mmol/L)
oUnspecified hypoglycemia :an event during which PG ≤70mg/dL (3.9 mmo l/L) 
but no informat ion relative to symptoms of hypoglycemia was recorded
Documented Clinically Significant Hypoglycemia (Level 2) PG <54 mg/dL 
(3.0mmol/L):
oSymptomatic hypoglycemia: an event during which typical symptoms of 
hypoglycemia are acco mpanied by PG <54 mg/dL (3.0 mmo l/L)
oAsymptomatic hypoglycemia: an event not accompanied by t ypical symptoms 
of hypoglycemia but with PG <54 mg/dL (3.0 mmol/L)
oUnspeci fied hypoglycemia
:an event during which PG <54 mg/dL (3.0 mmo l/L) 
but no informat ion relative to symptoms of hypoglycemia was recorded
I8F-MC-GPHI Clinical Pharmacology Protocol Page 34
Tirzepatide (LY 3298176 )Severe hypoglycemia (Level 3): an event requiring assistance o f another person to 
actively administer carbohy drate, gl ucagon, or oth er resuscitative act ions.  During these 
episodes, the subject has an altered mental status and cannot assist in their care, is 
semico nscious or unconscious, or experienced coma with or without seizures and may 
requi re parenteral  therapy .Plasma glucose measurements may not be available during 
such an event, but neurological recovery  attributable to the restoration of blood glucose 
concentration to normal is considered sufficient evidence that the event was induced by a 
low PG concentrati on (PG ≤70 mg/dL [3.9 mmo l/L])
oSevere hypoglycemia requiring medical attention :a severe hypoglycemic 
event when subjects requi re therapy  by healt hcare professio nals (e.g., emergency 
medical technicians , emergency  room  personnel)
Other Hypoglycemia:
Nocturnal hypoglycemia: any hypoglycemic event (documented symptomat ic, 
asymptomat ic, probable symptomat ic, or severe hypoglycemia) that occurs between 
bedtime and waking
Relative hypoglycemia: an event during which typical symptoms of hypoglycemia, that
do not requi re the assistance o f another person, are accompanied by  PG >70 mg/dL 
(3.9mmo l/L), but these levels may be quickly approaching the 70 mg/dL (3.9 mmo l/L) 
thresho ld
Overall (or total) hypoglycemia: This opti onal category  combines all cases o f 
hypoglycemia. If an event of hypoglycemia falls into mult iple subcategories, the event is 
only counted once in this category
Probable symptomatic hypoglycemia: An event during which symptoms of 
hypoglycemia are not accompanied by a PG measurement but that was presumably 
caused by  a blood gl ucose concentration ≤70 mg/dL (3.9 mmo l/L).
The determinat ion of a hypoglycemic event as an episode of severe hypoglycemia as defined 
above will be made by  the invest igator based on the medical need of the subject to hav e requi red 
assistance and is not predicated on the report of a subject simply having received assistance.
Hypoglyc emic events will be recorded i n the hypoglyc emia m odule of the eCRF to allow for the 
collect ion of co mprehensive safet y informat ion relating t o these events.  All episodes of severe 
hypoglycemia will addit ionally be reported as SAEs (see Section 9.2.1 for details regarding SAE 
reporting).
9.4.3. Vital Signs
For each subject , vital signs measurements should be conducted according to the Schedule of 
Activities (Secti on 2) 
Blood pressure and pulse rate should be measured after at least 5 minutes in the supine position.
Unscheduled orthostatic vital signs should be assessed, if possible, during any AE of dizziness or 
posture -induced symptoms.  Addit ional vital signs may be m easured during each treatm ent
period if warranted
.
I8F-MC-GPHI Clinical Pharmacology Protocol Page 35
Tirzepatide (LY 3298176 )9.4.4. Electrocardio grams
For each subject , single 12 -lead ECG sshoul d be collected according to the Schedule of 
Activities (Secti on 2).  
Any clinically  significant findings from ECGs that result in a diagnosis and that occur after the 
subject receives the first dose of the IP,shoul d be reported to Lilly ,or its desi gnee ,as an AE via 
eCRF.  
Electrocardiograms must be recorded before collecting any blood samples.
  Subjects must be 
supine for approximately  5 to 10 minutes before ECG collect ion and rem ain supine but awake 
during ECG collect ion.  Electrocardiograms may be obt ained at addit ional times,when deemed 
clinically necessar y.  All ECGs recorded should be stored at the invest igational site.
Electrocardiograms will be interpreted by  a qualified invest igator (a physician or qualified 
designee) at the site as soon after the time of ECG collect ion as possible, and ideally while the 
subject is st ill present, to determine whether the subject meets entry criteria at the relevant 
visit(s) and for immediate subject management, should any clinically relevant findings be 
ident ified.  
If a clinically significant finding is ident ified (including, but not limited to, changes in QT/QTc 
interval  from baseline) after enrollment, the investigator will determine if the subject can 
continue in the stud y.  The invest igator, or qualified de signee, is responsible for determining if 
any change in subject management is needed, and must document his/her review of the ECG 
printed at the time of co llection.  Any new clinically  relevant finding shoul d be reported as an 
adverse event.
9.4.5. Injection -SiteReactions
Inject ion-site assessments for l ocal tolerabilit y will be conducted, when reported as:
an AE fro m a subject, or
a clinical observat ion from an invest igator.
Reported inject ion-site reacti ons will  be characterized wi thin the fo llowing categori es:
edem a
erythema
induration
itching
pain
All injecti on-site reacti ons reported as AEs will be closely monitored until reso lution.  T he report 
of a clinically  significant AE of inject ion-site reacti on may prom pt notificati on of  the sponsor, 
clinical photogra phy, and referral for dermatologic evaluat ion and consideration of a skin biopsy 
I8F-MC-GPHI Clinical Pharmacology Protocol Page 36
Tirzepatide (LY 3298176 )and laboratory  evaluat ions (ALT, AST, complete blood coun t with percent eosinophils, and 
additional immunogenici ty testing).
Invest igational site staff will be provided with s eparate instructions/training on how to evaluate 
inject ion-site reacti ons and thei r severi ty in a consistent m anner.  Photographs of inject ion-site 
reacti ons may be taken in a standardized manner for record -keeping purposes; however, the 
photographs will n ot be used to eval uate the severity  of injecti on-site reacti on.
9.4.6. Hypersensitivity Reactions
All hypersensit ivity react ions will be reported by  the invest igator as either AEs or, if any serious 
criterion is met, as SAEs.
In the event of suspected drug hy persensitivity reacti ons (immediate or non -immediate) in 
subjects who experience moderate -to-severe injectio n reactions as assessed by the invest igator, 
unscheduled blood samples will be collected for PK and anti-drug ant ibody  (ADA )analyses at 
the following time points:  
as close as possible t o the onset of the event
at the resolut ion of the event
30 (±3) day s following the event   
Addit ionally , unscheduled serum  samples for immune safet y laboratory  testing (including, but 
not limited to β try ptase, total  immunoglobulin E, com plement and cy tokine panel testing) 
shoul d also be collected at approximately  60 to 120 minutes and 4 to 6 we eks after the onset of 
the event in these subjects .  
Instructi ons for the collect ion and handling of blood samples will be provided by the sponsor.  
The actual  date and time (24-hour clock time) of each sampling will be recorded.
9.4.7. Safety Monitoring
The Lil ly CP or CRP/sci entist will mo nitor safet y data throughout the course of the study .
Lilly will review SAEs wit hin timeframes mandated by  com pany procedures.  The Lilly  CPor 
CRP will periodically review the following data :
trends in safety  data
laboratory  analy tes including glucose, amylase, and lipase
serious and nonserious AEs, including AEs o f special interest
Further di agnosti c assessments will be recommended whenever lipase and/ or amylase are 
confirmed to be ≥3×ULN at any  visit postdose even if the subject is asymptomatic (as per the 
algorithm for the m onitoring of  pancreat ic events in Appendix 7 ) and ,if pancreat itis is suspected, 
the case will be further defined during an adjudicatio n process.
When appropriate, the Lilly CP or CRP will consult with the funct ionally  independent Gl obal 
Patient Safet y therapeutic area physician or clinical research scient ist.  
I8F-MC-GPHI Clinical Pharmacology Protocol Page 37
Tirzepatide (LY 3298176 )9.4.7.1. Hepatic Safety
If a study  subject experiences elevated ALT ≥3×ULN, ALP ≥2×ULN , or el evated TBL ≥2×
ULN, liver te sts (Appendix 4 ) shoul d be repeated wi thin 3 to5 day s including ALT, AST, ALP, 
TBL, direct bilirubin , gamma -glutamyl transferase ( GGT ),and creatine kinase to confirm the 
abnorm ality and to determine if it is increasing or decreasing.  If the abnormalit y persists or 
worsens, clinical and laboratory  monitoring shoul d be ini tiated by  the invest igator based on 
consultation wit h the Lilly CPor CRP.   Monitoring shoul d continue unt il levels norm alize and/or 
are return ingto approximate baseline levels. 
Addit ional safet y data should be co llected if 1or more of  the f ollowing condit ions occur: 
elevation of serum  ALT to ≥5×ULN on 2or more consecut ive blood tests
elevated serum TBL to ≥2×ULN 
elevation of serum  ALP to ≥2×ULN on 2or more consecut ive blood tests 
subject discontinued from treatment due to a hepatic event or abnormalit y of liver 
tests
hepatic event considered to be a SAE
9.5. Pharmacokinetic s
At the visit s and t imes specified in the Schedule of Act ivities(Secti on 2), venous blood samples 
of approximately  3mL each will be co llected to determine the plasma concentrations o f 
tirzepat ide.  A maximum o f 3 unscheduled samples may be collected at addit ional time points 
during the study  if warranted and agreed upon between both the investigator and sponsor.  
Instructi ons for the collect ion and handling of blood samples will be provided by the sponsor.  
The actual  date and time (24- hour clock time) of each sampl ing will be recorded.
Failure or being late (i.e. ,outsi de sti pulated time allowances) to perform procedures or obtain 
samples due to legit imate clinical issues (e.g. ,equipment technical problems, venous access 
difficult y, or subject default ing or turning up late on an agreed scheduled procedure) will not be 
considered as protocol deviat ions but the CRU will still be required to notify  the sponsor in 
writing via a file note. 
9.5.1. Bioanalysis
Samples will  be analyzed at a l aboratory  approved by  the sponsor and stored at a facilit y 
designated by  the sponsor .
Concentrations of tirzepat ide will be assayed using a validated liquid chro matography  tandem 
mass spectrometry  method.
Bioanaly tical samples collected to m easure IP concentrations will be retained for a maximum o f 
2 years fo llowing l ast subject visit for the stud y.  During thi s time, samples remaining after the 
bioanalyses may  be used for expl oratory  analyses, such as me tabolism work, protein binding, or 
bioanalyt ical method cross -validation .
I8F-MC-GPHI Clinical Pharmacology Protocol Page 38
Tirzepatide (LY 3298176 )9.5.2. Exploratory Assessments
9.5.2.1. Fat Deposition at Injection Site
The rel ationship between exposure to tirzepat ide and adiposit y at the injection site will be 
explored by use of skinfo ld cali pers and DEXA scanning.  
DEXA scanning will be performed at the times specified in the Schedule o f Activities 
(Secti on2).  Awhole body scan will be performed using a narrow angle fan beam DEXA 
scanner to estimate the total fat at the site of inject ion for the specific dosing period.
Skinfo ld thickness will be measured using skinfo ld calipers at the planned inject ion site of the 
specific dosing perio d.  A s far as possible, the same skinfo ld calipers will be used on each 
occasi on for all subjects.  Only a limited number of site personnel will perform the skinfo ld 
measurements for consistency .
Instructi ons will be provided separat elyto the investi gator detailing the skinfo ld calipers and 
DEXA measurements . 
9.5.2.2. Waist , Upper Arm, and Thigh Circumference
Waist , thigh, and upper arm  circumference will  be measured in triplicate , and the mean recorded,
as specified in the Schedule of Act ivities (Secti on 2).
9.6. Pharmacodynamic s
Not applicable .
9.7. Immunogenicity Assessments
For immunogenicit y testing, venous blood samples of approximately 10 mL will be collected 
from each subject according to the Schedule of Activit ies (Secti on 2) to determine ant ibody  
producti on against tirzepat ide.  
Up to 3 a dditional samples ma y be co llected if there is a 
possibilit y that an AE is immuno logically mediate d.  All samples for immunogenicit y testing 
shoul d have a time -matched sample for PK analysis where relevan t.  In the event of drug 
hypersensit ivity react ions (immediate or non -immediate ), addi tional unscheduled samples shoul d 
be co llected as detailed in Sect ion9.4.6 .  Instructions for the collection and handling of blood 
samples will be provided by  the sponsor.  The actual date an d 24-hour clock time o f each 
sampling will be recorded.
Immunogenicit y will be assessed by  a validated assay  designed to detect ADA in the presence of 
tirzepat ideat a l aboratory  approved by the sponsor .  Antibodies may be further evaluated for 
their abili ty to neutralize the activit y of tirzepat ideon GIP and GLP -1 receptors .  Positive 
tirzepat ideADA samples willbe tested for cross -reactivit y with native GIP and GLP -1, and, if 
positive, m ay then be tested for neutralizing ant ibodies against native GIP an d/or GLP -1.  
All subjects will have an ADA sample measured at early discont inuat ion or at the last planned 
study  visit.  Arisk-based approach will be used to mo nitor subj ects who devel op 
treatm ent-emergent ADA (TE ADA), defined in Section 10.3.3 (Evaluation of Immunogenicit y).
I8F-MC-GPHI Clinical Pharmacology Protocol Page 39
Tirzepatide (LY 3298176 )Clinically significant TE ADA will be defined as any TE ADA at the last visit with:
a high ti ter (1280) or an increasing titer from last measured value
an associ ation with a moderate -to-severe inject ionsite reacti on
Subjects who have clinically significant TE ADA at early  discontinuat ion or at the fo llow-up
visit shoul d be f ollowed wi th ADA testing every  3months until the ADA titers have return to the 
baseline ADA t iter (defined as ADA t iter wi thin 2- fold of baseline) or for up to 1 year, 
whichever i s less er.  A PK sample may be collected at the fo llow-up immunogenicit y 
assessment(s), if warranted and agreed upon by the invest igator and sponsor.
Every  attem pt shoul d be made to contact subjects for the fo llow-up immunogenicit y assessment; 
however, if subjects are unwilling or unable to return for the visit, this is not considered a 
protocol  deviat ion.
Subjects fo llowed f or at least 1 y ear after dosing who have not returned to baseline, as defined 
above, will be assessed for safet y concerns and, if no clinical sequelae are recognized by  the 
clinical team, no further fo llow-up will be require d.  Subjects who have cl inical sequelae that are 
considered potentially  related to the presence of TE ADA may  also be asked to return for 
additional follow-up testi ng.
Samples will  be retained for a m aximum  of 15 y ears after the last subject visit, or for a shorter 
period if loca l regulat ions and IRB allows ,at a facilit y selected by  the sponsor.  The durati on 
allows the sponsor to respond to future regulatory  requests rel ated to the tirzepat ide.  Any 
samples remaining after 15 y ears will be destroye d.  
9.8. Genetics
A blood sam ple will be collected for pharmacogenetic analysis as specified in the Schedule o f 
Activities (Section 2), where l ocal regulat ions allo w.  
Samples will notbe used to conduct unspecified disease or populat ion genet ic research either 
now or in the future.  Samples will be used to investigate variable exposure or response to 
tirzepat ide and to invest igate genet ic variants thought to play a role in T2DM.  A
ssessment of 
variable response may include evaluation of AEs or differences in efficac y.  
All samples will be coded with the subject number.  These samples and any  data generated can 
be linked back to the subject only by the invest igative site personne l. 
Samples will  be retained for a m aximum  of 15 y ears after the last subject visit, or for a shorter 
period if local  regulat ions and/or IRBs impose shorter time limits, for the study at a facilit y 
selected by  Lilly or i ts desi gnee.  This retention period en ables use of new techno logies, response 
to regulatory  quest ions, and invest igation of variable response that may  not be observed unt il 
later in the development of tirzepat ideor after tirzepatde is commercially available.  
Molecular techno logies are ex pected to improve during the 15 -year storage period and therefore 
cannot be specifically  name d.  H owever, exist ing approaches include who le geno me or exome 
sequencing, geno me wide association studies, multiplex assays, and candidate gene studies.  
I8F-MC-GPHI Clinical Pharmacology Protocol Page 40
Tirzepatide (LY 3298176 )Regardless of technol ogy utilized, data generated will be used only  for the specific research 
scope described in this sect ion.  
9.9. Biomarker s
Not applicable .  
9.10. Health Economics
Thissection is not applicable for this study.
I8F-MC-GPHI Clinical Pharmacology Protocol Page 41
Tirzepatide (LY 3298176 )10. Statistical Considerations and Data Analysis
10.1. Sample Size Determination
Approximately  54 subjects will be enrolled to ensure that at least 36 evaluable subjects complete 
the study ,with at least 12 subjects complet ing per treatment sequence.  Wit h 36 subjects, we 
expect the two one-sided t -tests (TOST) for equivalence applied to the log -norm al mean rat io to 
have a power of at least 98% for each of the 4 tests on the primary  objective.  This assumes a 
nominal expected mean ratio of 1.05, a coefficient variat ion of 19.6%, and significance level of 
0.05 of each one -sidedtest when testing against an upper limit of 1.25 and lower limit of 0.8 0.  
The source of the cho ice of coefficient of variat ion is fro m the final results of study  
I8F-MC-GPG E.  F or bal ance and the evaluat ion of the secondary  object iveof effect of BMI, the 
54 subjects will be enro lled according to their BMI category  such that each category  enrol ls 
approximately  27 subjects and retains 6 completers per treatment sequence.
10.2. Populations for Analyses
10.2.1. Study Participant Disposition
A detailed description o f subject disposit ion will be provided at the end of the stud y.  
All 
subjects who discontinue from the study  will be identified, and the extent of their participation in 
the study  will be reporte d.  If known, a reason for their discont inuation will be give n.  
10.2.2. Study Participant Characteristics
The subject’s age, sex, weight, height, BMI, or other demographic characterist ics will be 
recorded and may be used in the PK and safet y analyses as classification variables.
10.3. Statistical Analyses
Statistical analysis o f this study  will be the responsibilit y of Eli Lilly and Company  or its 
designee .
Pharmacokinet ic analyses will be conducted on data fro m all subjects who receive at least one 
dose of the IPand have evaluable dat a.  
Safety analyses will be conducted for all subjects who receive at least one dose of the IP, 
whether or not they  com pleted all protocol requirements.
Addit ional exploratory  analyses of the data will be conducted as deemed appropriate.  Study  
resul ts may be pool ed wi th the results of other studies for populat ion PKanalysis purposes.   
10.3.1. Safety Analyses
10.3.1.1. Clinical Evaluation of Safety
All IPand protocol  procedure AEs will be listed and study  device com plaint s, and if the 
frequency  of events all ows, safet y data will be sum marized using descriptive methodology .
I8F-MC-GPHI Clinical Pharmacology Protocol Page 42
Tirzepatide (LY 3298176 )The incidence of symptoms at each treatment period will be presented by severit y and by 
associ ation with IPas perceived by the invest igator.  Symptoms reported to occur prior to 
enrollment will be dist inguished from those reported as new or increased in severit y during the 
study.  Each symptom will be classified by the most suitable term fro m the medical  regulatory  
dictionary.
The number of IP-related SAEs will be reported.
10.3.1.2. Statistical Evaluation of Safety
Safety parameters that will be assessed include AEs,safet y laboratory param eters (including 
amylase, lipase, and blood glucose), andvital signs.  The param eters will  be listed, and 
summarized using standard descript ive statist ics, where appropri ate. 
Physical exami nations and ECGs will be performed for safet y monitoring purp oses and will not 
be presented.
Incidence of reported inject ion site reactions for erythema, indurat ion, pain, itching, and edema 
will be listed and summarized.
If warranted, a dditional analyses will be perform ed upon review of the data .
10.3.2. Pharmacokinetic Analyses
10.3.2.1. Pharmacokinetic Parameter Estimation
Pharmacokinet ic parameter estimates for tirzepat idewill be calculated by standard 
nonco mpart mental methods of analysis.
The primary  PK param eters f or analysis will be C maxand area under the concentration versus 
time curve fro m zero to infinit y (AUC [0-∞]).  O ther noncompartmental parameters, such as time 
to C max(tmax),area under the concentration versus time curve fro m zero to the last measrurable 
concentrati on (AUC[ 0-tlast]) , half -lifeassoci ated wi th the terminal rate constant in 
nonco mpart mental analysis (t 1/2), apparent clearance (CL/F) , and apparent volume of distribut ion
(V/F) may be reported .
10.3.2.2. Pharmacokinetic Statistical Inference
Pharmacokinet icparameter estimates will be evaluated to delineate effects of inject ion site. 
Log-transform ed AUC(0 -∞)and C maxwill be evaluated in a linear mixed -effects m odel with 
fixed effects for inject ion site, peri od,and sequence.  Subject nested within sequence will be 
fittedas a rando m effec t.  
For the primary  endpoint s, 
the following com parisons will be assessed:
Ratio of AUC( 0-∞) (90% confidence interval [CI]) and C max(90% CI) for:
Upper a rm (Test 1) : Abdo men (Reference)
Thigh (Test 2) : Abdom en (Reference)
I8F-MC-GPHI Clinical Pharmacology Protocol Page 43
Tirzepatide (LY 3298176 )Differences will be back -transform ed to present the ratios of geometric least squares means and 
the corresponding 90% CI.
For the secondary  endpoint, BMI group and the BMI group -by-injection site interact ionterm will 
be added to the above model.  Subject nested within sequence and BMI group will be fittedas a 
rando m effec t.  The effect of BMI group will be assessed overall, within each injection site, as 
well as between inject ion sites.  The comparisons that will be assessed are the fo llowing:
Ratio of AUC(0 -∞) (90% CI) an d Cmax(90% CI) for:
Low BMI group (Test) : High BMI group (Reference) - Overall
Low BMI group (Test) : High BMI group (Reference) - Abdo men
Low BMI group (Test) : High BMI group (Reference) - Arm
Low BMI group (Test) : High BMI group (Reference) -Thigh
Upper a rm (Test 1) : Abdo men (Reference) -Low BMI 
Upper a rm (Test 1) : Abdo men (Reference) -High BMI
Thigh (Test 2) : Abdom en (Reference) - Low BMI 
Thigh (Test 2) : Abdo men (Reference) -High BMI
Inject ion site will be de emed to show evidence of equivalence if the 90% CI is fully contained 
within the 0.8 0to 1.25 range.
In addit ion, AUC(0 -
tlast)will also be analyzed as an exploratory parameter using the same 
methodol ogy.
The t maxwill be analyzed ,using a non -parametri c approach for all o f the above co mpar isons. 
Estimates of the median difference, 90% CIs, and p -values fro m the Wilcoxon signed rank test 
will be calculated.
Relationship between exposure to tirzepati deand adiposity/body  com position param eters (i.e., 
skinfo ld thi ckness and fat deposit ion)at the injection sites and waist , thigh, and upper arm 
circumference m ay be expl ored if deemed appropriate.
Addit ional analyses, such as subgroup analyses ,may be carried out if appropriate .
10.3.3. Evaluation of Immunogenicity
The frequency and percentage of subjects wi th preexist ing ADA and with TE ADA+ to 
tirzepat idewill be tabulate d.  Treatm ent-emergent ADA are defined as those with a titer 2 -fold 
(1dilution) greater than the minimum required di lution if no ADA were detected at baseline 
(treatment -induced ADA) or those with a 4 -fold (2 dilut ions) increase in t iter compared to 
baseline if ADA were detected at baseline (treatment -boosted ADA ).  The minimum required
dilution of the ADA assay is 1:1 0.  For the TE ADA+ subjects the distributi on of  maximum  titers 
I8F-MC-GPHI Clinical Pharmacology Protocol Page 44
Tirzepatide (LY 3298176 )will be describe d.  The frequency of neutralizing ant ibodies , if assessed, and cross reactivit y to
native GIP and GLP -1 mayalso betabul ated in TE ADA+ subjects .
10.3.4. Data Review During the Study
Neither the Lilly study  team  nor the invest igator is blinded as the study  is open -label.  Data m ay 
be accessed while the trial is ongo ing, but no changes to the study design are planne d.  A n 
assessment committee will not be formed.
10.3.5. Interim Analyses
No interim analyses are pl anned for this stud y.  If an unplanned interim analysis is deemed 
necessary , the Lilly CP, CRP /investigator, or designee will consult with the appropriate medical 
director or desi gnee to determine if it is necessary  to am end the protocol .
I8F-MC-GPHI Clinical Pharmacology Protocol Page 45
Tirzepatide (LY 3298176 )11. References
American Diabetes Associat ion. 6. Glycemic targets: Standard of Medical Care in Diabetes –
2018. D iabetes Care. 2018;41(Supp l.  1):S55 -S64 2017 © by  the American Diabetes 
Associ ation.  
Banks PA, Freeman M L.  
Practice guidelines in acute pancreatit is. Am J Gastroentero l.  
2006;101(10):2379 - 2400 .
Coskun T, Sl oop K, Loghin C, Alsina -Fernandez J, Urva S, Bokvist KB, Cui X, Briere DA,
Cabrera O, Roell WC, Kuchibhot la U, Moyers JS, Benson CT, Gimeno RE, D’Alessio DA,
Haupt A.LY3298176, a novel dual GIP and GLP -1 receptor agonist for the treatment of ty pe 
2diabetes mellitus: Fro m discovery  to clinical  proof  of concep t.Molecular metabolis m.  
2018;18:3 - 14.
Frias JP, Nauck MA, Van J, Kutner ME, Cui X, Benson C, Urva S, Gimeno RE, Milicevic Z,
Robins D, Haupt A.Efficacy and safet y of LY3298176, a novel dual GIP and GLP -1 receptor
agonist, in pat ients with type 2 di abetes: a randomised, pl acebo -controlled and act ive
comparator -controlled phase 2 tria l.The Lancet. 2018;392(10160): 2180-2193.
International Hypoglycemia Study Grou p.  G lucose Concentrations of Less Than 3.0 mmo l/L
(54mg/dL) Should Be Reported in Clinical Trials: A Joint Posit ion Statement of the
American Diabetes Associat ion and the European Associat ion for the Study  of Diabetes. 
Diabetes Care . 2017;40(1):155 -157.
Koizumi M, Takada T, Kawarada Y, Hirata K, Mayumi T, Yoshida M, Sekimoto M, Hirota M, 
Kimura Y, Takeda K, Isaji S, Otsuki M, Matsuno S; JPN. JPN Guidelines for the management 
of acute pancreatitis: diagnostic criteria for acute pancreat itis. J Hepatobiliary Pancreat Surg. 
2006;13(1):25 -
32.
Steinberg WM, Buse JB, Ghorbani MLM, Ørsted DD, Nauck MA; LEADER Steering 
Committee; LEADER Trial Invest igators. Amylase, lipase, and acute pancreat itis in people 
with type 2 diabetes tre ated with liraglut ide: result s from the LEADER Rando mized Tria l.  
Diabetes Care. 2017a;40(7):966-972.
Steinberg WM, Rosenstock J, Wadden TA, Donsmark M, Jensen CB, DeVries J H.  
Impact of 
liraglutide on amylase, lipase, and acute pancreat itis in part icipant s with overwei ght/obesi ty 
and normoglycemia, prediabetes, or ty pe 2 di abetes: secondary  analyses of pool ed data from 
the SCALE clinical development progra m.  Diabetes Care. 2017b;40(7):839 -848.
I8F-MC-GPHI Clinical Pharmacology Protocol Page 46
Tirzepatide (LY 3298176 )12. Appendices
I8F-MC-GPHI Clinical Pharmacology Protocol Page 47
Tirzepatide (LY 3298176 )Appendix 1. Abbreviations and Definitions
I8F-MC-GPHI Clinical Pharmacology Protocol Page 48
Tirzepatide (LY 3298176 )Term Definition
ADA anti-drug antibody
AE adverse event:  Any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relatio nship with this treatmen t.  An AE can therefore be any unfavorable and unintended 
sign (including an abnormal laboratory finding), symptom, or disease temporally associated 
with the use of a medicinal (investigational) product, whether or not related to the medicinal 
(investigational) product.
ALP alkalin e phosphatase
ALT alanine aminotransferase
assent Agreement fro m a child or other individual who is not legally capable o f 
provi ding consent, but who can understand the circumstances and potential 
risks invo lved in participating in a study  (requi red by  some institutional 
review boards [IRBs]/ethical review boards [ERBs] ).  
AST aspartate aminotransferase
AUC(0 -∞) area under the concentration versus time curve from zero to infinity
AUC(0 -tlast) area under the concentration versus time curve from zero to the last measurable 
concentration
BMI body mass index
CI confidence interval
Cmax maximum drug concentration
complaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
compliance Adherence to all the study -related requirements, good clinical practice (GCP) requirements, 
and the applicable regulatory requirements.
confirmation A process used to confirm that laboratory test results meet the quality requirements defined 
by the laboratory generating the data and that Lilly is confident that results are accurate.  
Confirmation will either occur immediately after initial testing or will require that samples 
be held to be retested at some defined time point, depending on the steps required to obtain 
confirmed results.
CP Clinical Pharmacologist
CRF/eCRF case report form/electronic case report form
I8F-MC-GPHI Clinical Pharmacology Protocol Page 49
Tirzepatide (LY 3298176 )CRP Clinical Research Physician:  Individual responsible for the medical conduct of the stud y.  
Responsibilities of the CRP may be performed by a physician, clinical research scientist, 
global safety physician or other medical officer.
CRU clinical research unit
DEXA dual ene rgy x-ray absorptiometry
ECG electrocardiogram
enroll The act of assigning a subject to a treatmen t.  Subjects who are enrolled in the study are 
those who have been assigned to a treatment.
enter Subjects entered into a study are those who sign the informed consent form directly or 
through their legally acceptable representatives.
GCP good clinical practice
GI gastrointestinal
GIP glucose -dependent insulinotropic polypeptide
GLP-1 glucagon -like peptide -1
IB Investigator’s Brochure
ICF informed consent form
ICH International Council for Harmonization
informed consent A process by which a subject voluntarily confirms his or her willingness to participate in a 
particular study, after having been informed of all aspects of the study that a re relevant to 
the subject’s decision to participate.  Informed consent is documented by means of a 
written, signed and dated informed consent form.  
IP investigational product: Apharmaceutical form of an active ingredient or placebo being 
tested or used as a reference in a clinical study, including products already on the market 
when used or assembled (formulated or packaged) in a way different from the authorized 
form, or market ed products used for an unauthorized indication, or marketed products used 
to gain further information about the authorized form.
investigator A person responsible for the conduct of the clinical study at a study site.  If a study is 
conducted by a team o f individuals at a study site, the investigator is the responsible leader 
of the team and may be called the principal investigator.
IRB institutional review board
Legal 
RepresentativeAn individual or judicial or other body authorized under applicable law to consent, on 
behalf of a prospective subject, to the subject’s participation in the clinical study.
MAD multiple ascending dose
MTD maximum tolerated dose
I8F-MC-GPHI Clinical Pharmacology Protocol Page 50
Tirzepatide (LY 3298176 )open -label A study  in which there are no restrictions on knowledge of treatment allocation, therefore 
the investigator and the study participant are aware of the drug therapy received during the 
study.
randomize the process of assigning subjects/ patients to an experimental group on a random basis
PG plasma glucose
PK pharmacokinetic (s)
SAD single asending dose
SAE serious adverse event
SC subcutaneous(ly)
screen The act of determining if an individual meets minimum requirements to become part of a 
pool of potential candidates for participation in a clinical study .  
SUSAR suspected unex pected serious adverse reaction
T2DM type 2 diabetes mellitus
TBL total bilirubin
TE ADA treatment -
emergent anti -drug antibody
TEAE treatment -emergent adverse event :  Any untoward medical occurrence that emerges during 
a defined treatment period, having been absent pretreatment, or worsens relative to the 
pretreatment state ,anddoes not necessarily have to have a causal relationship with this 
treatment 
tmax time of maximum plasma concentration
ULN upper limit of normal
I8F-MC-GPHI Clinical Pharmacology Protocol Page 51
Tirzepatide (LY 3298176 )Appendix 2. Clinical Laboratory Tests
Safety Laboratory Tests
Hematology a Clinical Chemistry a
Hematocrit Sodium
Hemoglobin Potassium
Erythrocy te count (RBC) Bicarbonate
Mean cell volume Chloride
Mean cell hemoglobin Calcium
Mean cell hemoglobin concentration Glucose (fasting)
Leukocytes (WBC) Blood urea nitrogen
Platelets Total protein
Albumin
Absolute counts of: Total bilirubin
Neutrophils Alkaline phosphatase
Lymphocy tes Aspartate aminotransferase
Monocytes Alanine aminotransferase
Eosinophils Creatinine
Basophils Amylase
Lipase
Triglycerides
Urinaly sisa
Specific gravity Hepatitis B surface antigen c
pH Hepatitis C antibody c
Protein HIV or HIV antibody c
Glucose Pregnancy test d
Ketones FSH c,d
Bilirubin Urine drug screen
Urobilinogen Alcohol breath test
Blood
Nitrite
Leukocytes (WBC)
Microscopic examination of sediment b
Abbreviations:  FSH = follicle -stimulating hormone; HIV = human immunodeficiency virus; RBC = red blood cells; 
WBC = white blood cells.
aPerformed by local laborator y.  Results will be validated by the laboratory at the time of initial testing.
bTest only if dipstick result is abnormal (i .e., positive for blood, protein, or nitrites) if clinically indicated, per 
investigator discretion.
cPerformed by local laboratory at screening only.  
dFor women onl y.  Serum pregnancy test will be performed at screening and urine pregnancy tests at subsequent 
visits .  For women w ho are considered to be postmenopausal, a blood sample for follicle -stimulating hormone 
should be drawn at screening to confirm postmenopausal status as defined in inclusion criterion [1b]; women 
with confirmed nonchildbearing potential status can be exempted from further pregnancy tests during the study 
after screening.
I8F-MC-GPHI Clinical Pharmacology Protocol Page 52
Tirzepatide (LY 3298176 )Appendix 3. Study  Governance, Regulatory  and Ethical 
Considerations
Informed Consent
The invest igator is responsible for:
ensuring that the subject understands the nature of the study , the potential risks and 
benefits of part icipating in the study, and that their participat ion is vo luntary.
ensuring that inf ormed consent i s given by each subject or legal representative.  This 
includes obtaining the appropriate signatures and dates on the ICF prior to the 
perform ance of any protocol  procedures and prior to the administration of IP.
answering any quest ions the subject may have throughout the study  and sharing in a 
timely  manner any  new inform ation that m ay be relevant to the subject’s willingness to 
continue his or her participat ion in the study.
provi ding a copy  of the ICF to the participant or the participant’ s legal representative and 
retaining a copy  on file.
A legal representative must give informed consent for a child to participate in this stud y.  In 
addition to inform ed consent given by the legal representative, the child may  be requi red to give 
docum ented assent, if capable.
Recruitment
Lilly or i ts desi gnee is responsible for the central recruit ment strategy  for subj ects.  Individual 
investigators may have addit ional local requirements or processes.  Study -specific recruit ment 
materi al should be approved by Lilly .
Ethical Review
The invest igator must give assurance that the IRB was properly  consti tuted and convened as 
requi red by Internat ional Council for Harminosat ion (ICH) guidelines and other applicable laws 
and regulations.
Docum entati on of  IRB approval o f the protocol  and the ICF must be provided to Lilly  before the 
study  may begin at the investi gative si te.  Lilly or its representatives must approve the ICF 
before i t is used at the invest igative site.  All ICFs must be compliant with the ICH guideline on 
GCP.
The study  site’s IRB should be provided wit h the following:
the current IB and updates during the course of the study
ICF
relevant curri cula vi tae
I8F-MC-GPHI Clinical Pharmacology Protocol Page 53
Tirzepatide (LY 3298176 )Regulatory Considerations
This study  will be conducted in accordance wit h the protocol and with:
1)consensus ethics principles derived fro m internat ional ethics guidelines, 
including the Declarat ion of Helsinki and Council for International 
Organizat ions of Medical Sciences (CIOMS) Internat ional Ethi cal Guidelines 
2)applicable ICH GCP Guidelines 
3)applicable laws and regulations
Some of the obligat ions of the sponsor will be assigned to a third party  organizat ion.
Protocol Signatures
The sponsor’s responsible medical o fficer will approve the protocol, confirming that, to the best 
of his or her knowledge, the protocol accurately describes the planned design and conduct of the 
study.  
After reading the protocol, theprincipal invest igator will sign the protocol signature page and 
send a copy  of the signed page to a Lilly representative.
Final Report Signature
The invest igator or designee will sign the clinical study report for this study, indicat ing 
agreem ent wi th the analyses, results, and conclusio ns of the report.
The sponsor’s responsible medical o fficer and statistician will sign/approve t he final clinical 
study  report for this study , confirming that, to the best of his or her knowledge, the report 
accurately describes the conduct and results of the study .
Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the fo llowing:
provi de instructi onal materi al to the study  site, as appropriate.
provi detraining to i nstruct the invest igators and study  coordinators.  This training will 
give instruction on the protocol, the complet ion of the eCRF s, and study  procedures.
make periodic visit s to the study  site.
be available for consultation and stay  in contact with the study  site personnel by  mail, 
telephone, and/or fax.
review and evaluate eCRF data and/or use standard computer edits to detect erro rs in data 
collect ion.
conduct a qualit y review of the database .
I8F-MC-GPHI Clinical Pharmacology Protocol Page 54
Tirzepatide (LY 3298176 )In addit ion, Lilly or its representatives willperiodically check a sampl e of the subject data 
recorded against source documents at the study  site.  The study  may be audi ted by  Lilly and/or 
regulatory  agencies at any  time.  Invest igators will be given notice before an audit occurs.
The invest igator will keep records of all original source dat a.  This might include clinical 
laboratory  tests, m edical records, and clinical notes.  If requested, t he invest igator will provide 
the sponsor, applicable regulatory agencies, and applicable IRBs wi th direct access to the 
original  source docum ents.
Data Collection Tools/Source Data
An electronic data capture sy stem  will be used in this stud y.  The site must define and retain all 
source records and must maintain a record of any data where source data are directly entered into 
the data capture system.
Data Protection
Data systems used for the study  will have control s and requi rements in accordance with local 
data protecti on law.  
The purpose and use of subject personal information collected will be provided in a written 
docum ent to the subject by  the sponsor.
Study and Site Closure
Discontinuation of Study Site
Study  site parti cipat ion may be disco ntinued if Lilly  or its desi gnee , the invest igator, or the IRB 
of the study  sitejudges it necessary for medical , safet y, regulatory , or other reasons consistent 
with applicable l aws, regul ations, and GCP.
Discontinuation of the Study
The study  will be discontinued if Lilly or its designee judges it necessary  for m edical, safet y, 
regul atory , or other reasons consistent with applicable laws , regul ations, and GCP .
I8F-MC-GPHI Clinical Pharmacology Protocol Page 55
Tirzepatide (LY 3298176 )Appendix 4. Hepatic Monitoring Tests for Treatment -
Emergent A bnormality
Selected tests m ay be obtained in the event of a treatment -emergent hepatic abnormalit y and may  
be required in fo llow-up wi th subjects in consultation with Lilly or i ts desi gnee CRP .
Hepatic Monitoring Tests
Hepatic Hematology a Haptoglobin a
Hemoglobin
Hematocrit Hepatic Coagulation a
RBC Prothrom bin time
WBC Prothrombin time, INR
Neutrophils
Lymphocy tes Hepatic Serologies a,b
Monocytes Hepatitis A antibody, total
Eosinophils Hepatitis A antibody, IgM
Basophils Hepatitis B surface antigen
Platelets Hepatitis B surface antibody
Hepatitis B core antibody
Hepatic Chemistry a Hepatitis C antibody
Total bilirubin Hepatitis E antibody, IgG
Conjugated bilirubin Hepatitis E antibody, IgM
Alkaline phosphatase
ALT Anti -nuclear antibody a
AST Alkaline phosphatase isoenzymes a
GGT
Creatine kinaseAnti -smooth muscle antibody (or anti -actin 
antibody) a
Abbreviations:  ALT = alanine aminotransferase; AST = asp artate aminotransferase; GGT = gamma -glutamyl 
transferase; Ig = immunoglobulin; INR = international normalized ratio; RBC = red blood cells; WBC = white 
blood cells.
aAssay ed by Lilly -designated or local laboratory.
bReflex/confirmation dependent on regulatory requirements and/or testing availability .
I8F-MC-GPHI Clinical Pharmacology Protocol Page 56
Tirzepatide (LY 3298176 )Appendix 5. Blood Sampling Summary
This table summarizes the approximate number of venipunctures and blood volumes for all 
blood sam pling (screening, safet y laboratori es,and bioanaly tical assays) during the study.  
Protocol I8F-MC -GPHI Sampling Summary
PurposeBlood Volume per 
Sample (mL)Number of Blood 
SamplesTotal Volum e 
(mL)
Screening tests a 19.5 1 19.5
Clinical laboratory tests a 12.5 5 x 3 periods = 15 187.5
Pharmacokinetics b 3 14 x 3 periods (+3 
unscheduled) = 45135
Immunogenicity b 10 3 × 3 periods (+3 
unscheduled) = 12120
Blood glucose a 0.3 6 (+ 5 discard for 
cannula patency) x 3 
periods = 339.9
Pharmacogenetics 10 1 10
Total 481.9
Total for clinical purposes (rounded up to the nearest 10 mL) 490
aAdditional samples may be drawn if needed for safety purposes.
bUp to 3 additional unscheduled samples may be drawn based on emerging data .
I8F-MC-GPHI Clinical Pharmacology Protocol Page 57
Tirzepatide (LY 3298176 )Appendix 6. Classification of Contraceptive Methods
As per inclusio n criterion [1a], male subjects must use condoms plus one addi tional highly  
effect ive method of contraception or effect ive method of contraception as described below :
Highly Effective (Less Than 1% Failure Rate) Methods of Contraception:
Combined oral contraceptive pill and mini pill
NuvaRing
Implantable contraceptives
Injectable contraceptives (such as Depo -Provera®)
Intrauterine device (such as Mirena®and ParaGard®)
Contraceptive patch –ONLY women <198 pounds or 90 kg
Vasectomy  –for men in clinical trials
Effective Methods of Contraception:
Diaphragm  with spermicide
Cervical sponge
Cervical cap wit h spermicid e
I8F-MC-GPHI Clinical Pharmacology Protocol Page 58
Tirzepatide (LY 3298176 )Appendix 7. Pancreatic Monitoring
Glucagon -like peptide -1 agoni sts have been associated with a possible risk of acute pancreat itis.  
In2006, the United States prescribing informat ion for exenat ide was revised to include the event 
of pancreati tis.  In 2007, the United States prescribing information for this medicat ion was 
amended to include pancreat itis under “Precaut ions.”  Epi demi ologic studi es have indicated that 
there is an increased incidence and prevalence of pancreat itis in persons with T2DM.
To enhance understanding of the natural variability o f pancreat ic enzym es in the T2DM 
popul ation and, in order to assess for any potential effects of tirzepat ide on the exocrine 
pancreas, amylase and lipase values will be monitored in all current and future clinical trials wit h 
tirzepat ide.
Addit ional monitoring will be reque sted f or amylase or lipase values ≥3× the ULN at any  visit, 
even in asymptomat ic subjects (see figure below ).  Lipase and amylase may also be obtained at 
any time during the clinical trials for any  subject suspected of having symptoms suggest ive of 
exenati de pancreat itis (such as severe GI signs and/or symptoms), at the invest igator’s discretion.
Acute pancreat itis is an AE defined as an acute inflammatory  process of the pancreas that may 
also invo lve peripancreatic tissues and/or remote organ systems (Bank s and Freeman 2006).  
Thediagnosis of acute pancreat itis requires 2 of the fo llowing 3 features:
abdo minal pain characteristic of acute pancreatit is(Banks and Freeman 20 06; 
Koizumi et al.  2006)
serum  amylase and/or lipase ≥3× ULN
characterist ic findings of acute pancreat itis on computed tomography  scan or 
magnet ic resonance imaging
Most subjects with acute pancreatit is experience abdo minal pain that is located generally in the 
epigastri um, and radiates to the back in approximately  one-half of the cases. The pain is often 
associ ated wi th nausea and vo miting.  However, experience wit h GLP -1 agoni sts has 
demonstrated that som e subjects asymptomat ic for classic pancreatit is may demo nstrate 
significant el evations of lipase and/or amylase.  For subjects consid ered by  invest igators to be 
asymptomat ic for pancreat itis, but whose value(s) for lipase and/or amylase are ≥3× ULN, an 
algorithm is in place to fo llow these subjects safely  and to qui ckly reach (or n ot reach) a 
diagnosis of pancreat itis.
I8F-MC-GPHI Clinical Pharmacology Protocol Page 59
Tirzepatide (LY 3298176 )Abbreviations :  CBC = complete blood count; CT = computed tomography; MRI = magnetic resonance imaging ; 
ULN =upper limit of normal .

I8F-MC-GPHI Clinical Pharmacology Protocol Page 60
Tirzepatide (LY 3298176 )Subjects diagnosed with pancreat itis will be discontinued fro m the stud y.  Invest igators will be 
responsible for fo llowing, through an appropri ate heal thcare opti on, these pancreat itis AEs unt il 
the events resolve or are explaine d.  A dverse events that meet the diagnostic criteria of acute 
pancreat itis will be captured as SAEs.  For all other pancreatic AEs (such as idiopathic or 
asymptom atic pancreat ic enzyme abnormalit ies), the invest igator will be responsible for 
determining the seriousness of the event (AE or SAE) and the relatedness of the event to study  
drug.
Leo Document ID = 229f3842-d70a-45ec-a6fb-c336a6729db9
Approver: 
Approval Date & Time: 26-Jun-2019 18:35:03 GMT
Signature meaning: Approved
Approver: 
Approval Date & Time: 27-Jun-2019 14:05:52 GMT
Signature meaning: Approved
PPD
PPD